No retraction, correction or concern found when last checked on Oct 19, 2026.

Mitophagy in Alzheimer’s Disease and Other Age-Related Neurodegenerative Diseases

Qian Cai, Yu Young Jeong

Cells · 2020 · Review · CC BY

Abstract

Mitochondrial dysfunction is a central aspect of aging and neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and Huntington’s disease. Mitochondria are the main cellular energy powerhouses, supplying most of ATP by oxidative phosphorylation, which is required to fuel essential neuronal functions. Efficient removal of aged and dysfunctional mitochondria through mitophagy, a cargo-selective autophagy, is crucial for mitochondrial maintenance and neuronal health. Mechanistic studies into mitophagy have highlighted an integrated and elaborate cellular network that can regulate mitochondrial turnover. In this review, we provide an updated overview of the recent discoveries and advancements on the mitophagy pathways and discuss the molecular mechanisms underlying mitophagy defects in Alzheimer’s disease and other age-related neurodegenerative diseases, as well as the therapeutic potential of mitophagy-enhancing strategies to combat these disorders.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 20, 2026. Paragraph numbers are ours, so an answer can point at one.

1. Introduction

1Mitochondria are termed the “powerhouses” of the cell, and generate the majority of the cell’s supply of adenosine triphosphate (ATP) through the oxidative phosphorylation system (OXPHOS) in which electrons produced by the citric acid cycle are transferred down the mitochondrial respiratory complexes. Neurons have particularly high and continuous energy demands so that mitochondrial function is essential for maintaining neuronal integrity and responsiveness. Mitochondrial energy production fuels various critical neuronal functions, especially the ATP-dependent neurotransmission. Along with regulating energy levels, mitochondria have a high capacity to sequester excessive Ca2+ and release Ca2+ so as to prolong residual levels at synaptic terminals. Through this mechanism, mitochondria play essential roles in maintaining and regulating neurotransmission, as well as certain types of short-term synaptic plasticity. In addition, mounting evidence has demonstrated the critical role of mitochondria in the maintenance of cellular homeostasis. Glucose was shown to be an efficient energy source in neurons and glia that can consume energy produced in parallel by glycolysis and OXPHOS. However, upon neural network activation, the energy demand is robustly enhanced. Given ATP as the main energy source in neurons, mitochondrial energy metabolism thus may play a major role in supplying ATP to fuel these neuronal activities. Importantly, distinct mitochondrial energetic status might also have a significant impact on the cellular signaling pathways. Aged and dysfunctional mitochondria are defective in ATP production and Ca2+ buffering, leading to energy deficit and interruptions of neuronal function and health. Furthermore, damaged mitochondria trigger concomitant leakage of electrons and thus promote the production of harmful reactive oxygen species (ROS) that can damage nucleic acids, proteins, and membrane lipids. Moreover, mitochondrial oxidative stress leads to the release of cytochrome c, a mitochondrial intermembrane space protein, into the cytosol, inducing DNA damage, caspase activation, and apoptosis.

2A large body of work suggests that mitochondrial dysfunction underlies cognitive decline in neuronal aging and is one of the most notable hallmarks of age-associated neurodegenerative diseases. Mitochondrial damage causes energy deficit, oxidative stress, and impaired cellular signaling, which has been linked to the pathogenesis of neurodegeneration diseases. Given that a mitochondrion’s half-life is estimated to be about 30 days, cells have developed the interconnected and elaborate pathways through the balance of mitochondrial biogenesis and efficient removal of damaged mitochondria to ensure the maintenance of mitochondrial integrity and bioenergetic functions. Mitophagy, a selective form of autophagy, constitutes a key pathway of mitochondrial quality control mechanisms involving sequestration of defective mitochondria into autophagosomes for subsequent lysosomal degradation. Disruption of mitophagy has been indicated in aging and various diseases, including neurodegenerative disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington’s disease (HD). This review aims to provide a thorough and timely overview of the mitophagy pathways, summarize the underlying mechanisms of mitophagy defects in AD and other age-related neurodegenerative diseases, and highlight the possible therapeutic strategies targeting mitophagy towards confronting mitochondrial dysfunction and neurodegeneration.

2. Overview of the Mitophagy Pathways

3Mitophagy (mitochondrial autophagy) is the only known cellular pathway through which entire mitochondria are completely eliminated within lysosomes. Under physiological conditions, mitophagy plays an essential role in the basal mitochondrial turnover and maintenance. More importantly, mitophagy can also be robustly induced in response to a variety of pathological stimuli. There are a number of mitophagy pathways that have been identified (Figure 1).

2.1. PINK1-Parkin-Mediated Mitophagy

4PTEN-induced putative kinase protein 1 (PINK1)-Parkin-mediated mitophagy is the most heavily studied and the best-understood mitophagy pathway. In brief, loss of mitochondrial membrane potential (Δψm) accumulates PINK1 on the outer membrane of mitochondria (OMM) to recruit and activate Parkin, an E3 ubiquitin ligase, through phosphorylation of ubiquitin. Parkin then ubiquitinates a number of OMM proteins and subsequently activates the ubiquitin-proteasome system (UPS) to degrade these ubiquitinated OMM proteins. This leads to recruitment of the autophagy machinery to promote the engulfment of damaged mitochondria by phagophore or isolation membranes and thus formation of mitophagosomes destined for removal via the lysosomal system. The roles of PINK1 and Parkin in mitochondrial quality control and mitophagy have been supported by multiple studies in Drosophila. The PINK1-Parkin pathway was shown to facilitate mitophagy as well as selective mitochondrial respiratory chain turnover. Furthermore, genetic and clinical data have provided clear evidence to support the notion that the PINK1-Parkin pathway is involved in the pathogenesis of PD. However, recent in vivo studies indicate that PINK1 and Parkin are not critical for basal mitophagy in a range of tissues including the brain. More recent studies have been focused on understanding the PINK1-Parkin-independent mitophagy pathways.

2.2. Ubiquitin-Mediated Mitophagy Independent of Parkin

5Other E3 ubiquitin ligases that can also mediate removal dysfunctional mitochondria have been identified, which is with relation to PINK1-Parkin-independent mitophagy mechanisms. Mitochondrial ubiquitin ligase 1 (MUL1, also known as MAPL, GIDE, and MULAN) was reported to play a role in the regulation of mitophagy through multiple mechanisms. MUL1 interacts with mitochondrial fission GTPase protein dynamin-related protein 1 (Drp1) and mitochondrial fusion protein Mitofusin, both of which are the substrates of Parkin. MUL1 has no effect on PINK1-Parkin-mediated mitophagy, but can suppress PINK1 or Parkin mutant phenotypes in both Drosophila and mouse neurons. This suppression is attributed to the ubiquitin-dependent degradation of Mitofusin. Interestingly, double mutants of MUL1 with either PINK1 or Parkin show much more severe phenotypes. Moreover, MUL1 contains an LC3-interacting region (LIR) motif in the RING domain through which MUL1 interacts with GABAA receptor-associated protein (GABARAP), a member of the Atg8 family that plays a key role in autophagy and mitophagy. Thus, these observations collectively suggest that MUL1 functions in a pathway parallel to the PINK1-Parkin pathway. In addition to MUL1, a recent study reported PINK1-synphilin-1-SIAH-1 as another newly discovered Parkin-independent pathway that can promote PINK1-dependent mitophagy in the absence of Parkin.

2.3. Receptor-Mediated Mitophagy

6The BCL-2 homology 3 (BH3)-containing protein NIP3-like X (NIX, also known as BNIP3L), an OMM protein, was reported to play an important role in mitochondrial turnover in erythrocytes. NIX/BNIP3L contains an LIR motif at the amino-terminal that binds to LC3 on phagophore or isolation membranes, and is transcriptionally upregulated during erythrocyte differentiation. Such a mechanism enables NIX/BNIP3L to serve as a selective mitophagy receptor and promote recruitment of the autophagy machinery to the surface of damaged mitochondria in erythroid cells. NIX/BNIP3L was also reported to be involved in hypoxia-induced mitophagy, during which forkhead box O3 (FOXO3) and hypoxia-inducible factor (HIF) transcriptionally regulate NIX/BNIP3L along with BNIP3. Noteworthy, overexpression of NIX/BNIP3L can restore mitophagy in skin fibroblasts from PD patients carrying mutations in PARK6 or PARK2, suggesting an independent role of NIX/BNIP3L in PINK1-Parkin-mediated mitophagy. NIX/BNIP3L and BNIP3 were reported to be upregulated upon neuronal stress. However, the extent to which NIX/BNIP3L and BNIP3 might participate in neuronal mitophagy remains unclear. FUN14 domain containing 1 (FUNDC1) also functions as a mitophagy receptor and regulates the autophagic clearance of mitochondria under hypoxic stress. Studies have demonstrated that the mitochondrial phosphatase phosphoglycerate mutase family member 5 (PGAM5) dephosphorylates FUNDC1 to activate mitophagy during hypoxia. Additionally, FK506 Binding Protein 8 (FKBP8) was recently reported to have LIR domains and can mediate Parkin-independent mitophagy by recruiting LC3A. Collectively, these observations suggest that specific mitophagy receptors on the OMM play an essential role in recruiting the autophagy machinery to damaged mitochondria for lysosomal clearance.

2.4. Lipid-Mediated Mitophagy

7Recent studies have demonstrated that lipids can also act as an elimination signal to mediate recruitment of injured mitochondria to the autophagy pathway. Apart from ubiquitin- or receptor-mediated mitophagy, this pathway involves the direct interaction of LC3 with the phospholipid cardiolipin, and was originally observed in neuroblastoma cells and primary cortical neurons incubated with rotenone, staurosporine, or 6-hydroxydopamine. Cardiolipin is primarily found in the inner membrane of mitochondria (IMM) and is externalized to the OMM upon mitochondrial damage. Three enzymatic translocations are needed for the externalization of cardiolipin, which are mediated by the phospholipid scramblase-3 of mitochondria and the inner and outer membrane spanning hexameric complex of mitochondrial nucleoside diphosphate kinase D (NDPK-D/NM23-H4) in SH-SY5Y cells or Tafazzin (TAZ) in mouse embryonic fibroblasts (MEFs), respectively. Furthermore, cardiolipin interacts with LC3, and this interaction is facilitated by the negatively charged basic residues in LC3 and charged head group of cardiolipin. Thus, cardiolipin-mediated mitophagy is independent of PINK1 and Parkin. Importantly, cardiolipin downregulation or mutagenesis of LC3 at the sites predicted to interact with cardiolipin was shown to impair mitophagosome formation. In addition, genome-wide screens indicate that F-box and WD40 domain protein 7 (FBXW7), sterol regulatory element binding transcription factor 1 (SREBF1), and other components of the lipogenesis pathway may play a role in the regulation of Parkin-mediated mitophagy. Additionally, upon Drp1-mediated mitochondrial fission, ceramide was shown to promote autophagic recruitment of mitochondria through direct interaction of ceramide with LC3B-II.

2.5. Neuronal Mitophagy

8Neurons are highly polarized cells with unique properties in structure and function. Mitochondrial quality control mechanisms that efficiently sense and eliminate mitochondria damaged over usage, aging, or disease could be critical for neuronal health. Mitophagy is currently believed to constitute the major cellular pathway for mitochondrial quality control in neurons. While basal mitophagy is known to be required for the maintenance of neuronal homeostasis, mounting evidence has shown that mitophagy can be upregulated in response to various pathological stimuli (Figure 2). Cardiolipin-mediated mitophagy can be induced in primary cortical neurons treated with the mitochondrial complex I inhibitor rotenone. As for Parkin-mediated mitophagy, Δψm dissipation triggers Parkin translocation onto depolarized mitochondria in neurons after treatment with CCCP, an Δψm uncoupler. Interestingly, Parkin-targeted mitochondria primarily accumulate in the somatodendritic region of neurons where they undergo autophagic sequestration for lysosomal degradation. Moreover, mitophagy activation reduces anterograde transport, but increases retrograde transport of axonal mitochondria, suggesting that damaged mitochondria are trafficked back to the soma for mitophagic clearance. Parkin-dependent mitophagy was also discovered under AD-linked pathophysiological conditions in the absence of any Δψm dissipating reagent. The spatial aspects of Parkin-dependent mitophagy were also observed in vivo. In particular, the PINK1 and Parkin mutant Drosophila exhibit abnormal tubular and reticular mitochondria restricted to the cell body, as well as normal morphology with reduced mitochondrial flux within axons. In addition to Drosophila, the evidence from examination of Purkinje neurons in the mito-QC reporter mice suggests that the majority of mitochondrial turnover occurs in the Purkinje somata. This supports the view that damaged mitochondria or mitophagosomes are returned to the cell body for lysosomal clearance. Collectively, these in vitro and in vivo observations consistently suggest that the soma is in the focus of neuronal mitophagy, a selective process with a function to restrict damaged mitochondria to the soma and thus limit the impact of impaired mitochondrial function on distal axons.

2.6. Mitophagy In Vivo

9The mitophagy pathways have been extensively studied in vitro. To address the basal mitophagy in vivo, a number of transgenic mice expressing sensors to monitor the delivery of mitochondria to acidic organelles (lysosomes) have been developed. These studies have demonstrated active mitochondrial delivery to acidic organelles in multiple tissues but with variable rates. A recent work further shows that the basal mitophagy is independent of the PINK1 pathway. Consistently, studies from Drosophila expressing fluorescent mitophagy reporters, either mito-Keima or mito-QC, also reveal robust basal mitophagy in different tissues. However, null mutations of either PINK1 or Parkin do not lead to altered rates of mitochondrial delivery into lysosomes, suggesting nonessential roles of PINK1 and Parkin in the basal mitophagy in vivo. These data are also consistent with the observations from mice with the deletion of PARK6 or PARK2. These mice lack strong phenotypes, such as dopaminergic neuron loss. Importantly, the evidence of mitophagy activation is clear in the brain tissues of human patients with neurodegenerative diseases. Given multiple distinct mechanisms that have been identified to target damaged mitochondria for autophagy, other PINK1-Parkin-independent pathways or other as yet undefined mechanisms likely play more important role in the basal neuronal mitophagy. Therefore, the involvement of these mitophagy pathways in the basal mitochondrial turnover and in response to specific disease-related stressors needs to be carefully determined in vivo.

3. Mitochondrial Dysfunction in Neurodegenerative Diseases

10Mitochondrial defects are a significant concern in the aging nervous system and have been consistently linked to age-related neurodegenerative diseases, suggesting that the underlying mechanisms might be somewhat shared (Figure 3).

3.1. Aβ and Tau-Linked Mitochondrial Abnormalities

11AD is the most common form of neurodegenerative diseases in aging populations. Progression of the disease involves cognitive decline, memory loss, and neuronal death in the cerebral cortex and subcortical regions. AD patient brains are characterized by extracellular amyloid plaque deposits, composed of agglomerated amyloid β (Aβ) peptides, as well as intracellular accumulation of neurofibrillary tangles (NFTs), consisting of hyperphosphorylated tau (phospho-tau) protein. Mitochondrial disturbances have been suggested as a hallmark of AD as the patients exhibit early metabolic alterations prior to any histopathological or clinical manifestations. Mitochondrial dysfunction, oxidative stress, and mitochondrial DNA (mtDNA) changes are prominent pathological features reported in AD postmortem brains. Importantly, a growing body of evidence has indicated a major role of mitochondrial defects in the pathogenesis of AD.

12The degree of cognitive dysfunction in AD was linked to the extent of Aβ accumulation within mitochondria and mitochondrial abnormalities. Aβ has been proposed to be a key player in mediating mitochondrial damage. Aβ was found to impair multiple aspects of mitochondrial function, including function of the electron transport chain (ETC), ROS production, mitochondrial dynamics, and mitochondrial transport. The possible routes for Aβ to enter into mitochondria were thought to be through the translocase of the outer membrane (TOM) complex or mitochondrial-associated endoplasmic reticulum (ER) membrane (MAM). In addition to intracellular Aβ, mitochondria can also take up internalized extracellular Aβ. Aβ1–42 treatment was shown to lead to the opening of mitochondrial permeability transition pore (mPTP) in cultured cortical neural progenitor cells. While transient mPTP opening decreases cell proliferation, prolonged mPTP opening irreversibly causes cell death. Consistent with this observation, an interesting work in a live AD mouse model provided direct evidence that fragmented and defective mitochondria are limited to the vicinity of extracellular amyloid plaques that likely serve as a focal source to promote abnormal accumulation of Aβ within mitochondria and thus exacerbate Aβ-linked damage.

13The mechanisms underlying Aβ-mediated mitochondrial toxicity have been carefully investigated by several studies. The interactions of Aβ with Aβ-binding alcohol dehydrogenase (ABAD), a mitochondrial matrix protein, and cyclophilin D (CypD), a component of the mitochondrial transition pore, were reported to mediate Aβ-induced cytotoxic effects. In particular, ABAD was shown to be upregulated in AD neurons. Overexpression of ABAD can exacerbate Aβ-induced cellular oxidative stress and cell death. Aβ also forms a complex with CypD in the cortical regions of postmortem human AD patient brains and an AD mouse model. Deletion of CypD in AD mice rescues the mitochondrial phenotypes including impaired Ca2+ uptake, mitochondrial swelling due to increased Ca2+, depolarized Δψm, elevated oxidative stress, decrease in ADP-induced respiration control rate, and reduced complex IV activity and ATP levels. Moreover, CypD deficiency can improve synaptic function as well as learning and memory in an AD mouse model. These observations collectively suggest that Aβ-CypD interaction mediates AD-associated mitochondrial defects. Taken together, these pieces of evidence indicate that the aberrant accumulation of Aβ within mitochondria likely plays a causative role in impaired mitochondrial function in AD.

14Pathogenic forms of tau can also induce mitochondrial damage. A number of studies have demonstrated that phospho-tau specifically impairs complex I of the mitochondrial respiratory chain, resulting in increased ROS production, loss of Δψm, lipid peroxidation, and reduced activities of detoxifying enzymes such as superoxide dismutase (SOD). Overexpression of the mutant human tau protein htauP301L was reported to reduce ATP levels and increase susceptibility to oxidative stress in cultured neuroblastoma cells. Disrupted activity and altered composition of mitochondrial enzymes can also be detected in the P301S mouse model of tauopathy. In the pR5 mice overexpressing the htauP301L, mitochondrial dysfunction was evidenced by impaired mitochondrial respiration and ATP synthesis, decreased complex I activity, and increased ROS levels. Phospho-tau was also reported to directly interact with VDAC in AD brains. This interaction was proposed to impair mitochondrial function likely through blocking mitochondrial pores. Furthermore, mitochondrial stress was shown, in turn, to enhance hyperphosphorylation of tau in a mouse model lacking SOD2. Inhibition of mitochondrial complex I activity reduces ATP levels, resulting in a redistribution of tau from the axon to the soma and subsequent cell death. Thus, these observations suggest that the toxic effects of tau on mitochondria could be reciprocal and that mitochondrial deficiency might play a critical role in the development of tau pathology.

15Both Aβ and pathogenic tau have deleterious effects on mitochondrial dynamics through which impact mitochondrial function. Studies on postmortem brain tissues from human patients with AD and mouse models have demonstrated increased levels of Drp1 and Fis1 and reduced levels of mitofusin 1 (Mfn1), Mfn2, and OPA1. Moreover, Aβ overproduction, phospho-tau accumulation, as well as abnormal interactions of Drp1 with Aβ or phospho-tau cause excessive mitochondrial fission and fragmentation, which tend to increase as AD progresses. Cells overexpressing mutant tau associated with frontotemporal dementia (FTD) with Parkinsonism linked to chromosome 17 (FTDP-17) display decreased rates of mitochondrial fusion and fission and enhanced vulnerability to oxidative stress. Strikingly, reduction of Drp1 expression can protect against mutated tau-induced mitochondrial dysfunction. Collectively, these data suggest that the pathogenic forms of tau and Aβ could impair mitochondrial function either through direct interaction with VDAC, ABAD, or CypD, or indirectly through their toxic effects on mitochondrial dynamics.

3.2. Mitochondrial Defects with Synucleinopathies

16PD is the second most common form of neurodegenerative disease, which is characterized by the aberrant accumulation of α-synuclein (α-syn) in the form of Lewy bodies, especially in the substantia nigra. α-syn is abundant throughout the central nervous system and Lewy bodies are a defining feature of many clinical phenotypes known as synucleinopathies. Importantly, impaired mitochondrial function is also a pathological feature of both sporadic and familial PD. The relationship between α-syn and mitochondria has been explored in many studies. Some evidence showed that mitochondria could be the main targets of α-syn. In particular, the oligomerization and aggregation of α-syn can cause deficits in the complex I activities, leading to reduced ATP levels, depolarized Δψm, and the release of cytochrome c into the cytosol to trigger apoptosis. A number of studies have shown that α-syn is directly localized in mitochondria, and can be detected in isolated mitochondria from PD patient brains. Mitochondrial localization of α-syn has a negative impact on mitochondrial function, morphology, and dynamics. α-syn has a cryptic mitochondrial targeting sequence located at its amino terminal region through which α-syn is constitutively imported into mitochondria and associates with the IMM. Such a mechanism leads to reduced complex I activities and elevated ROS levels in human dopaminergic neurons. Moreover, oligomeric and dopamine-modified α-syn disrupts the association of the OMM translocase TOM20 and its coreceptor, TOM22, resulting in protein import impairment. Thus, diminished import of mitochondrial proteins impairs mitochondrial function in nigrostriatal neurons, as reflected by deficient respiration, loss of Δψm, and enhanced production of ROS.

17α-syn can also affect mitochondrial dynamics and mitophagy. Basically, α-syn is known to bind to the lipid membranes, especially the lipids of the ER membrane or the MAM through which ER interacts with mitochondria. Mutated α-syn decreases the ER-mitochondria contact or interaction, leading to MAM dysfunction and thus mitochondrial fragmentation. Other studies into PD have demonstrated that α-syn causes mitochondrial fragmentation through either direct binding or as a result of increased Drp1. Cleavage of Opa1 was found in dopaminergic neurons with overexpression of α-syn, resulting in decreased mitochondrial fusion. Consistently, suppression of Drp1-mediated mitochondrial fission was reported to protect cells from α-syn-induced cytotoxicity. In addition, studies have demonstrated the direct binding of α-syn to cardiolipin. Furthermore, PD-related SNCA-mutant neurons exhibit increased externalization of cardiolipin to the OMM. Externalized cardiolipin was shown to bind to and promote refolding α-syn fibrils. Importantly, the exposed cardiolipin initiates LC3 recruitment to mitochondria and thus enhances mitophagic turnover, leading to reduced mitochondrial volume and exacerbation of mutant α-syn-induced mitochondrial dysfunction. On the other hand, mitophagy defects were also proposed to play a significant role in PD pathogenesis, especially augmenting α-syn accumulation and its mediated neurotoxicity.

3.3. ALS and FTD-Associated Mitochondrial Toxicity

18ALS is a devastating disease characterized by motor neuron degeneration. A hallmark of ALS, as in the pathologies of other neurodegenerative diseases, is the abnormal accumulation of misfolded proteins and protein aggregates within the affected motor neurons. FTD affects the basal ganglia and cortical neurons, leading to cognitive deficits, language deficiency along with altered social behavior and conduct. Even though the affected neuron types are quite different, ALS and FTD show the similarities in genetic background and pathological processes and also share the common pathways of neurodegeneration. Defects in oxidative phosphorylation, Ca2+ buffering, and increased ROS production have been linked to ALS pathogenesis. Multiple studies in cell culture and in transgenic animal models of ALS reveal alterations in oxidative metabolism linked to changes in ETC activity and reduced ATP synthesis. More importantly, mitochondria purified from ALS patients display impaired Ca2+ homeostasis and increased ROS levels. Such defects are coupled with oxidative damage including altered tyrosine nitration and protein carbonylation. Indeed, glutamate-receptor mediated excitotoxicity was linked to overloaded mitochondrial Ca2+ and increased ROS levels in spinal motor neurons cultured from an ALS animal model.

19Aggregation of the transactive response DNA-binding protein 43 kDa (TDP-43) and fused in sarcoma (FUS) is the pathological hallmarks of both ALS and FTD. Both TDP-43 and FUS are ribonuclear proteins and contain the glycine molecule-enriched prion-like domains that can increase the propensity of TDP-43 and FUS for aggregation as well as cell-to-cell transmission. Aged animals expressing mutant FUS exhibit abnormal accumulation of ubiquitin-positive aggregates, which correlates with neuron loss. These aggregates also stain positive for mitochondrial protein cytochrome c, suggesting that damaged mitochondria recruit the autophagy machinery for removal through mitophagy. One study from a single postmortem analysis of an FUS mutation carrier uncovered similar defects. Additionally, C- and N-terminal fragments of TDP-43 were identified within mitochondria. Furthermore, animal models of TDP-43 pathology exhibit membranous organelle redistribution and clustering within cytoplasmic inclusions accompanied by morphological and ultrastructural alterations, as well as abnormal mitochondrial dynamics, trafficking, and quality control. Thus, these data consistently indicate the phenotypes of mislocalized, fragmented, and defective mitochondria associated with ALS and FTD.

3.4. Mutant Htt-Induced Mitochondrial Damage

20HD is a neurodegenerative genetic disease that affects muscle coordination and leads to cognitive decline and psychiatric symptoms. This autosomal dominant inherited neurodegenerative disease is the most common genetic cause of abnormal involuntary movements called chorea, and is characterized by mutations in the huntingtin gene (HTT) that result in abnormal expansion of the cytosine–adenine–guanine (CAG) trinucleotide repeats in the HTT gene, encoding a polyglutamine (polyQ) tract at the N-terminal region of the huntingtin (Htt) protein. The N-terminus of Htt can be cleaved through protease activity, leading to formation of short and toxic polyQ peptides. The N-terminal fragments of Htt containing the polyQ tracts are more prone to aggregation and accumulate within the inclusions in the nucleus especially in the medium spiny neurons of the striatum. Htt was reported to directly bind to Tim 23 on mitochondria, thus preventing the protein import into mitochondria. This defect could be reversed through overexpressing Tim 23. In addition, the aggregate accumulation can disrupt the ETC function. Moreover, studies in HD patient brains found decreased activities of complex II, complex III, and complex IV. Reduced complex II activity was observed particularly in the striatum of HD patients. Such defects along with reduced ATP production were also demonstrated in other studies, which collectively point towards impaired OXPHOS and disrupted mitochondrial energy metabolism. Importantly, overexpression of complex II reduces the mutant Htt-mediated toxic effects in striatal neurons. Moreover, alterations in mitochondrial dynamics were also reported in the striatum of HD patients, as well as in animal and cell models. Such a defect is caused by abnormal interaction of mutant Htt with Drp1, leading to Drp1-enhanced mitochondrial fission and thus mitochondrial fragmentation as well as cellular dysregulation and death.

4. Mitophagy Defects in Neurodegenerative Diseases

21Neurons have very high demand for ATP. Given that mitochondria are the major producer of ATP within cells, the nervous system is especially sensitive to mitochondrial damage. Inefficient elimination of injured mitochondria through mitophagy could be detrimental to neuronal health. Mitophagy deficit has been indicated in aging and the pathogenesis of age-associated neurodegenerative disorders. Studies into mitophagy suggest that defective mitophagy contributes to impaired mitochondrial function and neurodegeneration (Figure 4).

4.1. Mitophagy Defects in AD

22Earlier studies revealed abnormal mitophagy in AD patient brains, as evidenced by autophagic accumulation of mitochondria in the soma of vulnerable AD neurons. Among the multiple distinct mitophagy pathways, PINK1-Parkin-dependent mitophagy has been the focus of current studies in AD. We have shown that the Parkin pathway is robustly induced upon progressive Aβ accumulation and mitochondrial damage in human patient brains and animal models of AD. Furthermore, cytosolic Parkin is depleted in AD brains over the disease’s progression, resulting in mitophagic pathology and augmented mitochondrial defects. Consistently, in the AD patient-derived skin fibroblasts and brain biopsies, another study reported diminished Parkin along with abnormal PINK1 accumulation. Mitophagy can be restored in these cells by overexpression of Parkin, as reflected by decreased PINK1 and the recovery of Δψm coupled with reduced retention of defective mitochondria. Therefore, these findings indicate that impaired mitochondrial function and abnormal retention of dysfunctional mitochondria could be attributed to mitophagy defects in AD neurons. In addition, cardiolipin cluster-organized profile was shown to be lost in synaptic mitochondria purified from AD mouse models, occurring at the early disease stages and before nonsynaptic mitochondrial defects. This data suggests the possibility that cardiolipin-mediated mitophagy might be deficient in AD.

23The degradation capacity of lysosomes is critical for mitophagic clearance, and defects in lysosomal proteolysis of autophagic cargoes can also impair the mitophagy function. Lysosomal deficit is a prominent feature in AD brains, linked to the pathogenesis of AD. Suppression of lysosomal proteolysis in wild-type (WT) mice was shown to mimic neuropathology of AD and exacerbate autophagic pathology and amyloidogenesis in AD mouse models. Presenilin 1 mutations along with ApoE4, a key genetic risk factor of AD, are thought to disrupt lysosomal function. Other factors, including Aβ peptides, phospho-tau, ROS, and oxidized lipids and lipoproteins, could also impair lysosomal proteolysis and result in a toxic accumulation, thus triggering apoptosis and neuronal death in AD. Our recent study proposes that AD-linked lysosomal deficit is also attributed to defects in protease targeting to lysosomes. It is known that newly synthesized protease precursors need to be delivered from the trans-Golgi network (TGN) to the endo-lysosomal system for maturation, a process that relies on the presence of cation-independent mannose 6-phosphate receptor (CI-MPR) at the Golgi. The retromer complex mediates the retrieval of CI-MPR from late endosomes to the TGN and thus facilitates the trafficking of proteases to late endosomes and lysosomes. Our study reveals that retromer dysfunction and defective CI-MPR recycling to the Golgi lead to defects in protease targeting to lysosomes. As a result, protease deficit within lysosomes impedes lysosomal proteolysis of defective mitochondria along with other autophagic cargoes in AD neurons. Therefore, increased Parkin association with mitochondria, autophagic accumulation, as well as abnormal mitochondrial retention within lysosomes observed in AD neurons of patient brains and in cultured cells overexpressing mutant APP could also represent lysosomal deficiency. Taken together, these observations indicate that defective mitophagy is likely involved in AD-linked neurodegeneration.

24Pathogenic truncation of tau could impair mitophagy function. A recent work reported a stable association of an NH2-htau fragment with Parkin and Ubiquitin-C-terminal hydrolase L1 (UCHL-1) in cellular and animal AD models and human AD brains, leading to enhanced mitochondrial recruitment of Parkin and UCHL-1 and thus improper mitochondrial turnover. Mitophagy suppression can restore synaptic mitochondrial density and partially, but significantly, protect against neuronal death induced by this NH2-htau. In contrast, another study proposed that human wild type tau (htau) is inserted into the mitochondrial membrane, thus inducing mitophagy impairment. However, in a more recent study, both htau and htauP301L were shown to impair mitophagy in Caenorhabditis elegans (C. elegans) and neuroblastoma cells by reducing Parkin translocation onto mitochondria through a different mechanism. Instead of changes in the Δψm or the cytoskeleton, impaired Parkin recruitment to mitochondria is proposed to be caused by tau-mediated sequestration of Parkin in the cytosol. Collectively, these data suggest that mitophagy is impaired under tauopathy conditions by distinct mechanisms.

25In addition to defects in mitophagic clearance in response to Aβ and tau-induced mitochondrial damage, a recent study reveals a marked decrease in the basal level of mitophagy in postmortem hippocampal tissues from AD patients, cortical neurons derived from AD-induced pluripotent stem cell (iPSC), as well as AD mouse models. This study further demonstrates defects in the activation of ULK1 and TBK1, the autophagy proteins that mediate autophagy/mitophagy initiation, thus leading to impaired mitophagy function. Furthermore, pharmacological reinstallation of mitophagy mitigates amyloid and tau pathologies, resulting in beneficial effects against memory loss in these AD mice. Therefore, these data support the view that defective mitophagy is likely an early event in AD brains and plays a causative role in the development of AD-linked neuropathology. Further studies using neurons derived from iPSCs of sporadic AD or other similar models could be very critical to addressing whether mitophagy dysfunction serves as a key player in Aβ/tau proteinopathies.

4.2. Mitophagy Defects in PD

26Dysfunctional mitophagy is closely linked to PD. Many PD-causing genes show the mitochondrial phenotypes. In addition, PD patients have increased rates of mtDNA deletion in the substantia nigra, which further associates defective mitochondrial quality control with PD. The important role for mitophagy in PD was first indicated from an ultrastructural study showing autophagic accumulation of mitochondria in neurons of the patients with PD and Lewy Body Dementia (LBD). Many other studies have demonstrated mitophagy abnormalities in a variety of experimental models representing genetic forms of toxic-environmental PD. As previously discussed (see Section 2.1), cell-based and mechanistic studies directly link PINK1 and Parkin to mitophagy. However, while loss-of-function mutations in PARK6 (encoding PINK1) and PARK2 (encoding Parkin) genes are linked to familial PD, the role of the PINK1-Parkin-dependent pathway in vivo remains elusive. The PINK1 and Parkin pathway has been extensively studied in Drosophila. Mutant flies show dopaminergic degeneration, reduced lifespan, and locomotive defects. Muscle cells of mutant flies exhibited swollen mitochondria with disrupted cristae, coupled with muscle degeneration. PARK6 KO rats showed dopaminergic loss and motor defects. Importantly, both Drosophila and rat model systems show mitochondrial dysfunction. However, mice with the deletion of PARK6 or PARK2 do not exhibit robust substantial PD-relevant phenotypes. This might be due to compensations by other mechanisms that are sufficient enough to maintain neuronal homeostasis under physiological conditions. Strikingly, when crossing PARK2 KO mice with Mutator mice characterized by accelerated acquisition of mtDNA mutations, the resulting phenotypes have mitochondrial defects as well as dopaminergic neuronal loss. Thus, this observation suggests that Parkin-mutant mice are susceptible to increased mtDNA damage. Given that both impaired mitochondrial function and mitophagy deficit are the upstream of neurodegeneration, the lack of robust phenotypes in mice suggest that the PINK1-Parkin pathway might be dispensable under physiological conditions, yet still necessary in response to stress/pathological stimuli for the functional maintenance and survival of PD-related dopaminergic neurons. Aside from PINK1-Parkin-dependent mitophagy, increased cardiolipin-mediated mitophagy was proposed to play a role in α-syn-induced mitochondrial dysfunction.

4.3. Mitophagy Defects in ALS

27Impaired mitophagy was proposed to be involved in the denervation of neuromuscular junctions in an ALS mouse model. Additionally, lysosomal dysfunction has been implicated in ALS. A recent work has provided a strong evidence showing that lysosomal deficits play a critical role in autophagy/mitophagy dysfunction and mitochondrial pathology in a mutant SOD1 transgenic mouse model of ALS. Lysosomal deficits result in abnormal accumulation of autophagic vacuoles (AVs) engulfing damaged mitochondria within motor neuron axons of mutant SOD1 mice. More importantly, rescuing autophagy-lysosomal deficits was shown to enhance mitochondrial turnover, improve motor neuron survival, and ameliorate disease phenotype in mutant SOD1 mice. Given that autophagy/mitophagy is a lysosome-dependent pathway, defective mitophagy and mitochondrial pathology in ALS are attributed to defects in lysosomal proteolysis.

28A more recent study uncovers that Parkin-dependent mitophagy is activated in the mutant SOD1 mouse model of ALS. Mitophagy activation is known to induce Parkin-triggered and the UPS-mediated degradation of mitochondrial dynamics proteins Mfn2 and Mitochondrial Rho GTPase (Miro1). Consistently, increased mitophagy in the spinal cord of the mutant SOD1 mice is coupled with depletion of Parkin as well as mitochondrial dynamics proteins Mfn2 and Miro1 that are ubiquitinated by Parkin. Interestingly, genetic ablation of PARK2 protects against muscle denervation and motor neuron loss and attenuates the depletion of mitochondrial dynamics proteins, which delays disease progression and prolongs life span in mutant SOD1 mice. Thus, the results from this study suggest that Parkin could be a disease modifier of ALS, and chronic activation of Parkin-dependent mitophagy augments mitochondrial dysfunction by depleting mitochondrial dynamics proteins. Consistently, several other studies also reported a significant reduction of Miro1 in spinal cord tissue of ALS patients and animal models. Moreover, it was shown that Miro1 reduction induced by ALS-linked mutant SOD is dependent on Parkin. Miro1 is known as a component of the adaptor-motor complex essential for KIF5 motors to drive anterograde transport of mitochondria along axons. Miro1-knockout mice exhibit upper motor neuron degeneration. Thus, ALS-linked mitochondrial trafficking defect is likely caused by Miro1 deficiency as a result of Parkin-dependent enhancement of Miro1 turnover.

29Compromised mitophagy may also induce ALS. Many of the genes linked to ALS encode proteins that play a critical role in autophagy/mitophagy, including OPTN and p62, as well as their kinase TBK1. However, it is poorly understood how the mutations in these genes are involved in the ALS pathology. Given the phosphorylation of OPTN and p62 by TBK1 to activate autophagy/mitophagy, aberrant accumulation of misfolded proteins and protein aggregates along with impaired mitochondrial turnover may both contribute to ALS-linked mitochondrial dysfunction and motor neuron death. Illuminating the role of these proteins in vivo will be critical in dissecting the molecular and cellular mechanisms leading to axonal degeneration and motor neuron loss.

4.4. Mitophagy Defects in HD

30Mitochondrial dysfunction and autophagy failure have been linked to the pathogenesis of HD. Mutant Htt is known to be associated with mitochondria and to mediate mitochondrial damage. Defective mitophagy may also be involved in mitochondrial defects in HD. Decreased levels of the basal mitophagy were shown in the dentate gyrus of HD mice crossed with the mito-Keima mouse line. In addition to its role in catalyzing the sixth step of glycolysis, a recent study proposed that GAPDH functions in micro-mitophagy—the direct engulfment of injured mitochondria by lysosomes. In HD cell models, abnormal interaction of long polyQ tracts with mitochondrial GAPDH impairs GAPDH-mediated mitophagy, leading to mitochondrial dysfunction and increased cell death. Additionally, mutant Htt can interact with and affect the autophagy machinery. A primary defect in the ability of autophagosomes to recognize and recruit cytosolic cargoes was reported in HD cells, leading to inefficient autophagic engulfment of substrates including mitochondria. Such a defect contributes to HD-associated accumulation of abnormal mitochondria. Moreover, Htt was proposed to act as a scaffold protein for autophagy through the physical interaction of Htt with p62 and ULK1 proteins. This interaction allows Htt to facilitate p62-mediated cargo recognition efficiency, in particular, associating Lys-63-linked ubiquitin-modified substrates with LC3-II—the integral component of phagophore or isolation membranes. Thus, this study supports the possibility that polyQ expansion might compromise the role of Htt in autophagy. Given the evidence for HD-linked autophagy impairment and mitophagic pathology, investigations into mitophagy status as well as detailed mechanisms are important for better understanding of HD pathogenesis.

5. Mitophagy-Targeted Therapeutic Interventions

31From the above stated, it is clear that mitochondrial damage is a hallmark of major neurodegenerative diseases. Pharmacological agents that induce mitophagy with a goal of enhancing clearance of damaged mitochondria could be a promising strategy for achieving a significant therapeutic benefit. Several mitophagy inducers, including NAD+ precursors, urolithin A (UA), the antibiotic actinonin (AC), and spermidine, have been examined and shown significant benefits in enhancing mitophagy, increasing mitochondrial resistance to oxidative stress, prolonging health span, and for neuronal protection in disease animal models and/or human cells. The levels of NAD+ are reduced in AD animal models, and elevation of cellular NAD+ levels through supplementation with NAD+ precursors such as nicotinamide, nicotinamide mononucleotide (NMN), and nicotinamide riboside (NR) is found to attenuate Aβ and tau pathologies and protect against cognitive dysfunction. Such beneficial effects are attributed to the enhancement of the NAD+-dependent SIRT1 and SIRT3, expression of the transcription factor CREB, and enhanced activities of PI3K-Akt and MAPK/ERK1/2. Additionally, NAD+ replenishment was also shown to restore mitochondrial function and thus ameliorate dopaminergic neuron loss in iPSC and Drosophila models of PD. These observations collectively indicate that the interventions to sustain NAD+ levels might be beneficial for AD and PD patients.

32UA is an ellagitannins-derived metabolite, and can effectively induce neuronal mitophagy in both C. elegans and mouse brains. Both UA and AC-mediated mitophagy activation is dependent on PINK1, Parkin, and NIX, and was shown to attenuate AD pathologies, inflammation, and learning and memory deficits. Polyamines, including spermidine, can increase autophagy activity through affecting autophagy-related gene expression as well as enhance mitophagy through the mechanisms of mammalian target of rapamycin (mTOR) inhibition and 5′ AMP-activated protein kinase (AMPK) activation. Moreover, spermidine was shown to activate the Ataxia-Telangiesctasia mutated (ATM)-dependent PINK1/Parkin signaling. Treatment with spermidine can lead to memory improvement and prolonged life span observed in C. elegans, Drosophila, and mice.

33Other pharmacological strategies to enhance mitophagy through inducing mild bioenergetic stress or inhibiting mTOR activity have also been proven to be beneficial in either delaying or treating AD. Mitochondrial uncoupling agents such as 2,4-dinitrophenol (DNP) were reported to stimulate autophagy and preserve neuronal function in AD animal models. Through inducing mild bioenergetic stress and stimulating ketogenesis, 2-deoxyglucose treatment was found to protect neurons against degeneration in a mitochondrial toxin-based PD model, as well as enhance mitochondrial function and stimulate autophagic clearance of Aβ. The mTOR inhibitor rapamycin-mediated enhancement of autophagy/mitophagy and AMPK activation can induce mitochondrial clearance in a number of model organisms, including C. elegans, Drosophila, and mice. Rapamycin was also shown to reduce Aβ pathology and ameliorate cognitive dysfunction in a mutant APP transgenic mouse model. Similar to rapamycin, metformin can also stimulate mitophagy through inhibitions of mTOR and complex I activities and activations of AMPK, SIRT1, and Parkin-dependent mitophagy. Therefore, these observations collectively provide a strong rationale for future research into the compounds that can enhance mitophagy in AD models, such as UA, AC, and spermidine.

34In addition, mitophagy enhancement through activation of Parkin could be another promising strategy in some disease models. Nilotinib was originally identified as a tyrosine kinase inhibitor, and was recently reported to increase Parkin abundance and ubiquitination potentially through enhancing Parkin recycling via the proteasome system. Nilotinib-mediated c-ABL inhibition can also prevent tyrosine phosphorylation of Parkin, leading to the release of Parkin auto-inhibition status. Such a mechanism was demonstrated to be protective in PD models. Moreover, chronic treatment with nilotinib in APP transgenic mice can enhance Aβ clearance through increasing the interaction of Parkin with Beclin 1. As for ALS and FTD, nilotinib treatment was also reported to mitigate motor and cognitive deficits in TDP-43 transgenic mice.

6. Concluding Remarks

35Mitochondrial health is vital for cellular and organismal homeostasis, and mitochondrial defects have long been linked to the pathogenesis of neurodegenerative diseases such as AD, PD, ALS, HD, and others. However, it is still unclear whether cellular mechanisms required for the maintenance of mitochondrial integrity and function are deficient in these diseases, thus exacerbating mitochondrial pathology. The quality control of mitochondria involves multiple levels of strategies to protect against mitochondrial damage and maintain a healthy mitochondrial population within cells. In neurons, mitophagy serves as a major pathway of the quality control mechanisms for the removal of aged and defective mitochondria through lysosomal proteolysis. The molecular and cellular mechanisms that govern mitophagy have been extensively studied in the past decade. However, mitophagy deficit has only been recognized recently as a key player involved in aging and neurodegeneration. Given the fact that mitochondrial deficit is clearly linked to neuronal dysfunction and the exacerbation of disease defects, protection of mitochondrial function could be a practical strategy to promote neuroprotection and modify disease pathology. Mitochondrially targeted antioxidants have been proposed. In particular, the antioxidant MitoQ, a redox active ubiquinone targeted to mitochondria, has been examined and demonstrated to have positive effects in multiple models of aging and neurodegenerative disorders. Importantly, mitophagy could be another promising target for drug discovery strategy. Therefore, further detailed studies to elucidate mitophagy mechanisms not only advance our understanding of the mitochondrial phenotypes and disease pathogenesis, but also suggest potential therapeutic strategies to combat neurodegenerative diseases.

References 258

1.
Sheng Z.H., Cai Q. Mitochondrial transport in neurons: Impact on synaptic homeostasis and neurodegeneration. Nat. Rev. Neurosci. 2012;13:77-93.
Not in our library10.1038/nrn3156
2.
Alterations in Mitochondrial Quality Control in Alzheimer’s Disease · 2016
No notice
3.
Cai Q., Tammineni P. Mitochondrial Aspects of Synaptic Dysfunction in Alzheimer’s Disease. J. Alzheimers Dis. 2017;57:1087-1103.
Not in our library10.3233/jad-160726
4.
Chamberlain K.A., Sheng Z.H. Mechanisms for the maintenance and regulation of axonal energy supply. J. Neurosci. Res. 2019;97:897-913.
Not in our library10.1002/jnr.24411
5.
Nicholls D.G., Budd S.L. Mitochondria and neuronal survival. Physiol. Rev. 2000;80:315-360.
Not in our library10.1152/physrev.2000.80.1.315
6.
Mishra P., Chan D.C. Mitochondrial dynamics and inheritance during cell division, development and disease. Nat. Rev. Mol. Cell Biol. 2014;15:634-646.
Not in our library10.1038/nrm3877
7.
Lou G., Palikaras K., Lautrup S., Scheibye-Knudsen M., Tavernarakis N., Fang E.F. Mitophagy and Neuroprotection. Trends Mol. Med. 2019.
Not in our library10.1016/j.molmed.2019.07.002
8.
Devine M.J., Kittler J.T. Mitochondria at the neuronal presynapse in health and disease. Nat. Rev. Neurosci. 2018;19:63-80.
Not in our library10.1038/nrn.2017.170
9.
Werth J.L., Thayer S.A. Mitochondria buffer physiological calcium loads in cultured rat dorsal root ganglion neurons. J. Neurosci. 1994;14:348-356.
Not in our library10.1523/jneurosci.14-01-00348.1994
10.
Tang Y., Zucker R.S. Mitochondrial involvement in post-tetanic potentiation of synaptic transmission. Neuron. 1997;18:483-491.
Not in our library10.1016/s0896-6273(00)81248-9
11.
Billups B., Forsythe I.D. Presynaptic mitochondrial calcium sequestration influences transmission at mammalian central synapses. J. Neurosci. 2002;22:5840-5847.
Not in our library10.1523/jneurosci.22-14-05840.2002
12.
David G., Barrett E.F. Mitochondrial Ca2+ uptake prevents desynchronization of quantal release and minimizes depletion during repetitive stimulation of mouse motor nerve terminals. J. Physiol. 2003;548:425-438.
Not in our library10.1113/jphysiol.2002.035196
13.
Levy M., Faas G.C., Saggau P., Craigen W.J., Sweatt J.D. Mitochondrial regulation of synaptic plasticity in the hippocampus. J. Biol. Chem. 2003;278:17727-17734.
Not in our library10.1074/jbc.m212878200
14.
Kang J.S., Tian J.H., Pan P.Y., Zald P., Li C., Deng C., Sheng Z.H. Docking of axonal mitochondria by syntaphilin controls their mobility and affects short-term facilitation. Cell. 2008;132:137-148.
Not in our library10.1016/j.cell.2007.11.024
15.
Wallace D.C. A mitochondrial bioenergetic etiology of disease. J. Clin. Investig. 2013;123:1405-1412.
Not in our library10.1172/jci61398
16.
Wallace D.C. Mitochondrial diseases in man and mouse. Science. 1999;283:1482-1488.
Not in our library10.1126/science.283.5407.1482
17.
Finkel T., Holbrook N.J. Oxidants, oxidative stress and the biology of ageing. Nature. 2000;408:239-247.
Not in our library10.1038/35041687
18.
Court F.A., Coleman M.P. Mitochondria as a central sensor for axonal degenerative stimuli. Trends Neurosci. 2012;35:364-372.
Not in our library10.1016/j.tins.2012.04.001
19.
Lin M.T., Beal M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443:787-795.
Not in our library10.1038/nature05292
20.
Bose A., Beal M.F. Mitochondrial dysfunction in Parkinson’s disease. J. Neurochem. 2016;139(Suppl. 1):216-231.
Not in our library10.1111/jnc.13731
21.
Fivenson E.M., Lautrup S., Sun N., Scheibye-Knudsen M., Stevnsner T., Nilsen H., Bohr V.A., Fang E.F. Mitophagy in neurodegeneration and aging. Neurochem. Int. 2017;109:202-209.
Not in our library10.1016/j.neuint.2017.02.007
22.
Gross N.J., Getz G.S., Rabinowitz M. Apparent turnover of mitochondrial deoxyribonucleic acid and mitochondrial phospholipids in the tissues of the rat. J. Biol. Chem. 1969;244:1552-1562.
Not in our library
23.
Menzies R.A., Gold P.H. The turnover of mitochondria in a variety of tissues of young adult and aged rats. J. Biol. Chem. 1971;246:2425-2429.
Not in our library
24.
Youle R.J., Narendra D.P. Mechanisms of mitophagy. Nat. Rev. Mol. Cell Biol. 2011;12:9-14.
Not in our library10.1038/nrm3028
25.
Pickles S., Vigie P., Youle R.J. Mitophagy and Quality Control Mechanisms in Mitochondrial Maintenance. Curr. Biol. 2018;28:R170-R185.
Not in our library10.1016/j.cub.2018.01.004
26.
Chu C.T. Mechanisms of selective autophagy and mitophagy: Implications for neurodegenerative diseases. Neurobiol. Dis. 2019;122:23-34.
Not in our library10.1016/j.nbd.2018.07.015
27.
Palikaras K., Lionaki E., Tavernarakis N. Mechanisms of mitophagy in cellular homeostasis, physiology and pathology. Nat. Cell Biol. 2018;20:1013-1022.
Not in our library10.1038/s41556-018-0176-2
28.
Clark I.E., Dodson M.W., Jiang C., Cao J.H., Huh J.R., Seol J.H., Yoo S.J., Hay B.A., Guo M. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature. 2006;441:1162-1166.
Not in our library10.1038/nature04779
29.
Gautier C.A., Kitada T., Shen J. Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress. Proc. Natl. Acad. Sci. USA. 2008;105:11364-11369.
Not in our library10.1073/pnas.0802076105
30.
Narendra D., Tanaka A., Suen D.F., Youle R.J. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J. Cell. Biol. 2008;183:795-803.
Not in our library10.1083/jcb.200809125
31.
Kawajiri S., Saiki S., Sato S., Sato F., Hatano T., Eguchi H., Hattori N. PINK1 is recruited to mitochondria with parkin and associates with LC3 in mitophagy. FEBS Lett. 2010;584:1073-1079.
Not in our library10.1016/j.febslet.2010.02.016
32.
Matsuda N., Sato S., Shiba K., Okatsu K., Saisho K., Gautier C.A., Sou Y.S., Saiki S., Kawajiri S., Sato F., et al. PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J. Cell Biol. 2010;189:211-221.
Not in our library10.1083/jcb.200910140
33.
PINK1 Is Selectively Stabilized on Impaired Mitochondria to Activate Parkin · 2010
No notice
34.
Shiba-Fukushima K., Imai Y., Yoshida S., Ishihama Y., Kanao T., Sato S., Hattori N. PINK1-mediated phosphorylation of the Parkin ubiquitin-like domain primes mitochondrial translocation of Parkin and regulates mitophagy. Sci. Rep. 2012;2:1002.
Not in our library10.1038/srep01002
35.
Kane L.A., Lazarou M., Fogel A.I., Li Y., Yamano K., Sarraf S.A., Banerjee S., Youle R.J. PINK1 phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity. J. Cell Biol. 2014;205:143-153.
Not in our library10.1083/jcb.201402104
36.
Parkin is activated by PINK1-dependent phosphorylation of ubiquitin at Ser65 · 2014
No notice
37.
Phosphorylation of Parkin at Serine65 is essential for activation: elaboration of a Miro1 substrate-based assay of Parkin E3 ligase activity · 2014
No notice
38.
Koyano F., Okatsu K., Kosako H., Tamura Y., Go E., Kimura M., Kimura Y., Tsuchiya H., Yoshihara H., Hirokawa T., et al. Ubiquitin is phosphorylated by PINK1 to activate parkin. Nature. 2014;510:162-166.
Not in our library10.1038/nature13392
39.
Geisler S., Holmstrom K.M., Skujat D., Fiesel F.C., Rothfuss O.C., Kahle P.J., Springer W. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat. Cell Biol. 2010;12:119-131.
Not in our library10.1038/ncb2012
40.
The Mitochondrial Fusion-Promoting Factor Mitofusin Is a Substrate of the PINK1/Parkin Pathway · 2010
No notice
41.
Ziviani E., Tao R.N., Whitworth A.J. Drosophila parkin requires PINK1 for mitochondrial translocation and ubiquitinates mitofusin. Proc. Natl. Acad. Sci. USA. 2010;107:5018-5023.
Not in our library10.1073/pnas.0913485107
42.
Chan N.C., Salazar A.M., Pham A.H., Sweredoski M.J., Kolawa N.J., Graham R.L., Hess S., Chan D.C. Broad activation of the ubiquitin-proteasome system by Parkin is critical for mitophagy. Hum. Mol. Genet. 2011;20:1726-1737.
Not in our library10.1093/hmg/ddr048
43.
Yoshii S.R., Kishi C., Ishihara N., Mizushima N. Parkin mediates proteasome-dependent protein degradation and rupture of the outer mitochondrial membrane. J. Biol. Chem. 2011;286:19630-19640.
Not in our library10.1074/jbc.m110.209338
44.
Park J., Lee S.B., Lee S., Kim Y., Song S., Kim S., Bae E., Kim J., Shong M., Kim J.M., et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature. 2006;441:1157-1161.
Not in our library10.1038/nature04788
45.
Vincow E.S., Merrihew G., Thomas R.E., Shulman N.J., Beyer R.P., MacCoss M.J., Pallanck L.J. The PINK1-Parkin pathway promotes both mitophagy and selective respiratory chain turnover in vivo. Proc. Natl. Acad. Sci. USA. 2013;110:6400-6405.
Not in our library10.1073/pnas.1221132110
46.
Devireddy S., Liu A., Lampe T., Hollenbeck P.J. The Organization of Mitochondrial Quality Control and Life Cycle in the Nervous System In Vivo in the Absence of PINK1. J. Neurosci. 2015;35:9391-9401.
Not in our library10.1523/jneurosci.1198-15.2015
47.
Sung H., Tandarich L.C., Nguyen K., Hollenbeck P.J. Compartmentalized Regulation of Parkin-Mediated Mitochondrial Quality Control in the Drosophila Nervous System In Vivo. J. Neurosci. 2016;36:7375-7391.
Not in our library10.1523/jneurosci.0633-16.2016
48.
Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392:605-608.
Not in our library10.1038/33416
49.
Valente E.M., Abou-Sleiman P.M., Caputo V., Muqit M.M., Harvey K., Gispert S., Ali Z., Del Turco D., Bentivoglio A.R., Healy D.G., et al. Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Science. 2004;304:1158-1160.
Not in our library10.1126/science.1096284
50.
Basal mitophagy is widespread in Drosophila but minimally affected by loss of Pink1 or parkin · 2018
No notice
51.
Phosphorylation of Parkin at serine 65 is essential for its activation in vivo · 2018
No notice
52.
Villa E., Marchetti S., Ricci J.E. No Parkin Zone: Mitophagy without Parkin. Trends Cell Biol. 2018;28:882-895.
Not in our library10.1016/j.tcb.2018.07.004
53.
Braschi E., Zunino R., McBride H.M. MAPL is a new mitochondrial SUMO E3 ligase that regulates mitochondrial fission. EMBO Rep. 2009;10:748-754.
Not in our library10.1038/embor.2009.86
54.
MUL1 acts in parallel to the PINK1/parkin pathway in regulating mitofusin and compensates for loss of PINK1/parkin · 2014
No notice
55.
Ambivero C.T., Cilenti L., Main S., Zervos A.S. Mulan E3 ubiquitin ligase interacts with multiple E2 conjugating enzymes and participates in mitophagy by recruiting GABARAP. Cell Signal. 2014;26:2921-2929.
Not in our library10.1016/j.cellsig.2014.09.004
56.
Szargel R., Shani V., Abd Elghani F., Mekies L.N., Liani E., Rott R., Engelender S. The PINK1, synphilin-1 and SIAH-1 complex constitutes a novel mitophagy pathway. Hum. Mol. Genet. 2016;25:3476-3490.
Not in our library10.1093/hmg/ddw189
57.
Sandoval H., Thiagarajan P., Dasgupta S.K., Schumacher A., Prchal J.T., Chen M., Wang J. Essential role for Nix in autophagic maturation of erythroid cells. Nature. 2008;454:232-235.
Not in our library10.1038/nature07006
58.
Novak I., Kirkin V., McEwan D.G., Zhang J., Wild P., Rozenknop A., Rogov V., Lohr F., Popovic D., Occhipinti A., et al. Nix is a selective autophagy receptor for mitochondrial clearance. EMBO Rep. 2010;11:45-51.
Not in our library10.1038/embor.2009.256
59.
Liu L., Sakakibara K., Chen Q., Okamoto K. Receptor-mediated mitophagy in yeast and mammalian systems. Cell Res. 2014;24:787-795.
Not in our library10.1038/cr.2014.75
60.
Nix restores mitophagy and mitochondrial function to protect against PINK1/Parkin-related Parkinson’s disease · 2017
No notice
61.
Schweers R.L., Zhang J., Randall M.S., Loyd M.R., Li W., Dorsey F.C., Kundu M., Opferman J.T., Cleveland J.L., Miller J.L., et al. NIX is required for programmed mitochondrial clearance during reticulocyte maturation. Proc. Natl. Acad. Sci. USA. 2007;104:19500-19505.
Not in our library10.1073/pnas.0708818104
62.
Yeh S.H., Ou L.C., Gean P.W., Hung J.J., Chang W.C. Selective inhibition of early—But not late—Expressed HIF-1alpha is neuroprotective in rats after focal ischemic brain damage. Brain Pathol. 2011;21:249-262.
Not in our library10.1111/j.1750-3639.2010.00443.x
63.
Liu L., Feng D., Chen G., Chen M., Zheng Q., Song P., Ma Q., Zhu C., Wang R., Qi W., et al. Mitochondrial outer-membrane protein FUNDC1 mediates hypoxia-induced mitophagy in mammalian cells. Nat. Cell Biol. 2012;14:177-185.
Not in our library10.1038/ncb2422
64.
Chen G., Han Z., Feng D., Chen Y., Chen L., Wu H., Huang L., Zhou C., Cai X., Fu C., et al. A regulatory signaling loop comprising the PGAM5 phosphatase and CK2 controls receptor-mediated mitophagy. Mol. Cell. 2014;54:362-377.
Not in our library10.1016/j.molcel.2014.02.034
65.
Structural insights into the recognition of phosphorylated FUNDC1 by LC3B in mitophagy · 2016
No notice
66.
Bhujabal Z., Birgisdottir A.B., Sjottem E., Brenne H.B., Overvatn A., Habisov S., Kirkin V., Lamark T., Johansen T. FKBP8 recruits LC3A to mediate Parkin-independent mitophagy. EMBO Rep. 2017;18:947-961.
Not in our library10.15252/embr.201643147
67.
Chu C.T., Ji J., Dagda R.K., Jiang J.F., Tyurina Y.Y., Kapralov A.A., Tyurin V.A., Yanamala N., Shrivastava I.H., Mohammadyani D., et al. Cardiolipin externalization to the outer mitochondrial membrane acts as an elimination signal for mitophagy in neuronal cells. Nat. Cell Biol. 2013;15:1197-1205.
Not in our library10.1038/ncb2837
68.
Kagan V.E., Jiang J., Huang Z., Tyurina Y.Y., Desbourdes C., Cottet-Rousselle C., Dar H.H., Verma M., Tyurin V.A., Kapralov A.A., et al. NDPK-D (NM23-H4)-mediated externalization of cardiolipin enables elimination of depolarized mitochondria by mitophagy. Cell Death Differ. 2016;23:1140-1151.
Not in our library10.1038/cdd.2015.160
69.
Schlattner U., Tokarska-Schlattner M., Ramirez S., Tyurina Y.Y., Amoscato A.A., Mohammadyani D., Huang Z., Jiang J., Yanamala N., Seffouh A., et al. Dual function of mitochondrial Nm23-H4 protein in phosphotransfer and intermembrane lipid transfer: A cardiolipin-dependent switch. J. Biol. Chem. 2013;288:111-121.
Not in our library10.1074/jbc.m112.408633
70.
Ivatt R.M., Sanchez-Martinez A., Godena V.K., Brown S., Ziviani E., Whitworth A.J. Genome-wide RNAi screen identifies the Parkinson disease GWAS risk locus SREBF1 as a regulator of mitophagy. Proc. Natl. Acad. Sci. USA. 2014;111:8494-8499.
Not in our library10.1073/pnas.1321207111
71.
Sentelle R.D., Senkal C.E., Jiang W., Ponnusamy S., Gencer S., Selvam S.P., Ramshesh V.K., Peterson Y.K., Lemasters J.J., Szulc Z.M., et al. Ceramide targets autophagosomes to mitochondria and induces lethal mitophagy. Nat. Chem. Biol. 2012;8:831-838.
Not in our library10.1038/nchembio.1059
72.
Cai Q., Zakaria H.M., Simone A., Sheng Z.H. Spatial parkin translocation and degradation of damaged mitochondria via mitophagy in live cortical neurons. Curr. Biol. 2012;22:545-552.
Not in our library10.1016/j.cub.2012.02.005
73.
Cai Q., Zakaria H.M., Sheng Z.H. Long time-lapse imaging reveals unique features of PARK2/Parkin-mediated mitophagy in mature cortical neurons. Autophagy. 2012;8:976-978.
Not in our library10.4161/auto.20218
74.
Ye X., Sun X., Starovoytov V., Cai Q. Parkin-mediated mitophagy in mutant hAPP neurons and Alzheimer’s disease patient brains. Hum. Mol. Genet. 2015;24:2938-2951.
Not in our library10.1093/hmg/ddv056
75.
McWilliams T.G., Prescott A.R., Allen G.F., Tamjar J., Munson M.J., Thomson C., Muqit M.M., Ganley I.G. mito-QC illuminates mitophagy and mitochondrial architecture in vivo. J. Cell Biol. 2016;214:333-345.
Not in our library10.1083/jcb.201603039
76.
Sun N., Yun J., Liu J., Malide D., Liu C., Rovira I.I., Holmstrom K.M., Fergusson M.M., Yoo Y.H., Combs C.A., et al. Measuring In Vivo Mitophagy. Mol. Cell. 2015;60:685-696.
Not in our library10.1016/j.molcel.2015.10.009
77.
Goldberg M.S., Fleming S.M., Palacino J.J., Cepeda C., Lam H.A., Bhatnagar A., Meloni E.G., Wu N., Ackerson L.C., Klapstein G.J., et al. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J. Biol. Chem. 2003;278:43628-43635.
Not in our library10.1074/jbc.m308947200
78.
Itier J.M., Ibanez P., Mena M.A., Abbas N., Cohen-Salmon C., Bohme G.A., Laville M., Pratt J., Corti O., Pradier L., et al. Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum. Mol. Genet. 2003;12:2277-2291.
Not in our library10.1093/hmg/ddg239
79.
Perez F.A., Palmiter R.D. Parkin-deficient mice are not a robust model of parkinsonism. Proc. Natl. Acad. Sci. USA. 2005;102:2174-2179.
Not in our library10.1073/pnas.0409598102
80.
Increased Mitochondrial Calcium Sensitivity and Abnormal Expression of Innate Immunity Genes Precede Dopaminergic Defects in Pink1-Deficient Mice · 2011
No notice
81.
Kitada T., Pisani A., Porter D.R., Yamaguchi H., Tscherter A., Martella G., Bonsi P., Zhang C., Pothos E.N., Shen J. Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice. Proc. Natl. Acad. Sci. USA. 2007;104:11441-11446.
Not in our library10.1073/pnas.0702717104
82.
Fiesel F.C., Ando M., Hudec R., Hill A.R., Castanedes-Casey M., Caulfield T.R., Moussaud-Lamodiere E.L., Stankowski J.N., Bauer P.O., Lorenzo-Betancor O., et al. (Patho-)physiological relevance of PINK1-dependent ubiquitin phosphorylation. EMBO Rep. 2015;16:1114-1130.
Not in our library10.15252/embr.201540514
83.
Zhu J.H., Guo F., Shelburne J., Watkins S., Chu C.T. Localization of phosphorylated ERK/MAP kinases to mitochondria and autophagosomes in Lewy body diseases. Brain Pathol. 2003;13:473-481.
Not in our library10.1111/j.1750-3639.2003.tb00478.x
84.
Gibson G.E., Shi Q. A mitocentric view of Alzheimer’s disease suggests multi-faceted treatments. J. Alzheimers Dis. 2010;20(Suppl. 2):S591-S607.
Not in our library10.3233/jad-2010-100336
85.
Smith M.A., Perry G., Richey P.L., Sayre L.M., Anderson V.E., Beal M.F., Kowall N. Oxidative damage in Alzheimer’s. Nature. 1996;382:120-121.
Not in our library10.1038/382120b0
86.
Maurer I., Zierz S., Moller H.J. A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiol. Aging. 2000;21:455-462.
Not in our library10.1016/s0197-4580(00)00112-3
87.
Hirai K., Aliev G., Nunomura A., Fujioka H., Russell R.L., Atwood C.S., Johnson A.B., Kress Y., Vinters H.V., Tabaton M., et al. Mitochondrial abnormalities in Alzheimer’s disease. J. Neurosci. 2001;21:3017-3023.
Not in our library10.1523/jneurosci.21-09-03017.2001
88.
Devi L., Prabhu B.M., Galati D.F., Avadhani N.G., Anandatheerthavarada H.K. Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer’s disease brain is associated with mitochondrial dysfunction. J. Neurosci. 2006;26:9057-9068.
Not in our library10.1523/jneurosci.1469-06.2006
89.
Caspersen C., Wang N., Yao J., Sosunov A., Chen X., Lustbader J.W., Xu H.W., Stern D., McKhann G., Yan S.D. Mitochondrial Abeta: A potential focal point for neuronal metabolic dysfunction in Alzheimer’s disease. FASEB J. 2005;19:2040-2041.
Not in our library10.1096/fj.05-3735fje
90.
Manczak M., Park B.S., Jung Y., Reddy P.H. Differential expression of oxidative phosphorylation genes in patients with Alzheimer’s disease: Implications for early mitochondrial dysfunction and oxidative damage. Neuromolecular Med. 2004;5:147-162.
Not in our library10.1385/nmm:5:2:147
91.
Manczak M., Calkins M.J., Reddy P.H. Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer’s disease: Implications for neuronal damage. Hum. Mol. Genet. 2011;20:2495-2509.
Not in our library10.1093/hmg/ddr139
92.
Parker W.D., Filley C.M., Parks J.K. Cytochrome oxidase deficiency in Alzheimer’s disease. Neurology. 1990;40:1302-1303.
Not in our library10.1212/wnl.40.8.1302
93.
Butterfield D.A., Drake J., Pocernich C., Castegna A. Evidence of oxidative damage in Alzheimer’s disease brain: Central role for amyloid beta-peptide. Trends Mol. Med. 2001;7:548-554.
Not in our library10.1016/s1471-4914(01)02173-6
94.
Lin M.T., Simon D.K., Ahn C.H., Kim L.M., Beal M.F. High aggregate burden of somatic mtDNA point mutations in aging and Alzheimer’s disease brain. Hum. Mol. Genet. 2002;11:133-145.
Not in our library10.1093/hmg/11.2.133
95.
Coskun P.E., Beal M.F., Wallace D.C. Alzheimer’s brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proc. Natl. Acad. Sci. USA. 2004;101:10726-10731.
Not in our library10.1073/pnas.0403649101
96.
Reddy P.H., Beal M.F. Are mitochondria critical in the pathogenesis of Alzheimer’s disease? Brain Res. Brain Res. Rev. 2005;49:618-632.
Not in our library10.1016/j.brainresrev.2005.03.004
97.
Reddy P.H., Reddy T.P., Manczak M., Calkins M.J., Shirendeb U., Mao P. Dynamin-related protein 1 and mitochondrial fragmentation in neurodegenerative diseases. Brain Res. Rev. 2011;67:103-118.
Not in our library10.1016/j.brainresrev.2010.11.004
98.
Kerr J.S., Adriaanse B.A., Greig N.H., Mattson M.P., Cader M.Z., Bohr V.A., Fang E.F. Mitophagy and Alzheimer’s Disease: Cellular and Molecular Mechanisms. Trends Neurosci. 2017;40:151-166.
Not in our library10.1016/j.tins.2017.01.002
99.
Dragicevic N., Mamcarz M., Zhu Y., Buzzeo R., Tan J., Arendash G.W., Bradshaw P.C. Mitochondrial amyloid-beta levels are associated with the extent of mitochondrial dysfunction in different brain regions and the degree of cognitive impairment in Alzheimer’s transgenic mice. J. Alzheimers Dis. 2010;20(Suppl. 2):S535-S550.
Not in our library10.3233/jad-2010-100342
100.
Mattson M.P., Partin J., Begley J.G. Amyloid beta-peptide induces apoptosis-related events in synapses and dendrites. Brain Res. 1998;807:167-176.
Not in our library10.1016/s0006-8993(98)00763-x
101.
Lustbader J.W., Cirilli M., Lin C., Xu H.W., Takuma K., Wang N., Caspersen C., Chen X., Pollak S., Chaney M., et al. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer’s disease. Science. 2004;304:448-452.
Not in our library10.1126/science.1091230
102.
Du H., Guo L., Fang F., Chen D., Sosunov A.A., McKhann G.M., Yan Y., Wang C., Zhang H., Molkentin J.D., et al. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer’s disease. Nat. Med. 2008;14:1097-1105.
Not in our library10.1038/nm.1868
103.
Manczak M., Mao P., Calkins M.J., Cornea A., Reddy A.P., Murphy M.P., Szeto H.H., Park B., Reddy P.H. Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer’s disease neurons. J. Alzheimers Dis. 2010;20(Suppl. 2):S609-S631.
Not in our library10.3233/jad-2010-100564
104.
Keller J.N., Pang Z., Geddes J.W., Begley J.G., Germeyer A., Waeg G., Mattson M.P. Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid beta-peptide: Role of the lipid peroxidation product 4-hydroxynonenal. J. Neurochem. 1997;69:273-284.
Not in our library10.1046/j.1471-4159.1997.69010273.x
105.
Abramov A.Y., Canevari L., Duchen M.R. Beta-amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. J. Neurosci. 2004;24:565-575.
Not in our library10.1523/jneurosci.4042-03.2004
106.
Manczak M., Anekonda T.S., Henson E., Park B.S., Quinn J., Reddy P.H. Mitochondria are a direct site of A beta accumulation in Alzheimer’s disease neurons: Implications for free radical generation and oxidative damage in disease progression. Hum. Mol. Genet. 2006;15:1437-1449.
Not in our library10.1093/hmg/ddl066
107.
Wang X., Su B., Siedlak S.L., Moreira P.I., Fujioka H., Wang Y., Casadesus G., Zhu X. Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc. Natl. Acad. Sci. USA. 2008;105:19318-19323.
Not in our library10.1073/pnas.0804871105
108.
Manczak M., Reddy P.H. Abnormal interaction between the mitochondrial fission protein Drp1 and hyperphosphorylated tau in Alzheimer’s disease neurons: Implications for mitochondrial dysfunction and neuronal damage. Hum. Mol. Genet. 2012;21:2538-2547.
Not in our library10.1093/hmg/dds072
109.
Rui Y., Tiwari P., Xie Z., Zheng J.Q. Acute impairment of mitochondrial trafficking by beta-amyloid peptides in hippocampal neurons. J. Neurosci. 2006;26:10480-10487.
Not in our library10.1523/jneurosci.3231-06.2006
110.
Du H., Guo L., Yan S., Sosunov A.A., McKhann G.M., Yan S.S. Early deficits in synaptic mitochondria in an Alzheimer’s disease mouse model. Proc. Natl. Acad. Sci. USA. 2010;107:18670-18675.
Not in our library10.1073/pnas.1006586107
111.
Calkins M.J., Manczak M., Mao P., Shirendeb U., Reddy P.H. Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer’s disease. Hum. Mol. Genet. 2011;20:4515-4529.
Not in our library10.1093/hmg/ddr381
112.
Del Prete D., Suski J.M., Oules B., Debayle D., Gay A.S., Lacas-Gervais S., Bussiere R., Bauer C., Pinton P., Paterlini-Brechot P., et al. Localization and Processing of the Amyloid-beta Protein Precursor in Mitochondria-Associated Membranes. J. Alzheimers Dis. 2017;55:1549-1570.
Not in our library10.3233/jad-160953
113.
Schreiner B., Hedskog L., Wiehager B., Ankarcrona M. Amyloid-beta peptides are generated in mitochondria-associated endoplasmic reticulum membranes. J. Alzheimers Dis. 2015;43:369-374.
Not in our library10.3233/jad-132543
114.
Hansson Petersen C.A., Alikhani N., Behbahani H., Wiehager B., Pavlov P.F., Alafuzoff I., Leinonen V., Ito A., Winblad B., Glaser E., et al. The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc. Natl. Acad. Sci. USA. 2008;105:13145-13150.
Not in our library10.1073/pnas.0806192105
115.
Pinho C.M., Teixeira P.F., Glaser E. Mitochondrial import and degradation of amyloid-beta peptide. Biochim. Biophys. Acta. 2014;1837:1069-1074.
Not in our library10.1016/j.bbabio.2014.02.007
116.
Hedskog L., Pinho C.M., Filadi R., Ronnback A., Hertwig L., Wiehager B., Larssen P., Gellhaar S., Sandebring A., Westerlund M., et al. Modulation of the endoplasmic reticulum-mitochondria interface in Alzheimer’s disease and related models. Proc. Natl. Acad. Sci. USA. 2013;110:7916-7921.
Not in our library10.1073/pnas.1300677110
117.
Hou Y., Ghosh P., Wan R., Ouyang X., Cheng H., Mattson M.P., Cheng A. Permeability transition pore-mediated mitochondrial superoxide flashes mediate an early inhibitory effect of amyloid beta1-42 on neural progenitor cell proliferation. Neurobiol. Aging. 2014;35:975-989.
Not in our library10.1016/j.neurobiolaging.2013.11.002
118.
Xie H., Guan J., Borrelli L.A., Xu J., Serrano-Pozo A., Bacskai B.J. Mitochondrial alterations near amyloid plaques in an Alzheimer’s disease mouse model. J. Neurosci. 2013;33:17042-17051.
Not in our library10.1523/jneurosci.1836-13.2013
119.
Eckert A., Nisbet R., Grimm A., Gotz J. March separate, strike together—Role of phosphorylated TAU in mitochondrial dysfunction in Alzheimer’s disease. Biochim. Biophys. Acta. 2014;1842:1258-1266.
Not in our library10.1016/j.bbadis.2013.08.013
120.
Spires-Jones T.L., Hyman B.T. The intersection of amyloid beta and tau at synapses in Alzheimer’s disease. Neuron. 2014;82:756-771.
Not in our library10.1016/j.neuron.2014.05.004
121.
Schulz K.L., Eckert A., Rhein V., Mai S., Haase W., Reichert A.S., Jendrach M., Muller W.E., Leuner K. A new link to mitochondrial impairment in tauopathies. Mol. Neurobiol. 2012;46:205-216.
Not in our library10.1007/s12035-012-8308-3
122.
Dumont M., Stack C., Elipenahli C., Jainuddin S., Gerges M., Starkova N.N., Yang L., Starkov A.A., Beal F. Behavioral deficit, oxidative stress, and mitochondrial dysfunction precede tau pathology in P301S transgenic mice. FASEB J. 2011;25:4063-4072.
Not in our library10.1096/fj.11-186650
123.
Gotz J., Chen F., van Dorpe J., Nitsch R.M. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science. 2001;293:1491-1495.
Not in our library10.1126/science.1062097
124.
David D.C., Hauptmann S., Scherping I., Schuessel K., Keil U., Rizzu P., Ravid R., Drose S., Brandt U., Muller W.E., et al. Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice. J. Biol. Chem. 2005;280:23802-23814.
Not in our library10.1074/jbc.m500356200
125.
Manczak M., Reddy P.H. Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer’s disease. Hum. Mol. Genet. 2012;21:5131-5146.
Not in our library10.1093/hmg/dds360
126.
Mitochondrial Oxidative Stress Causes Hyperphosphorylation of Tau · 2007
No notice
127.
Escobar-Khondiker M., Hollerhage M., Muriel M.P., Champy P., Bach A., Depienne C., Respondek G., Yamada E.S., Lannuzel A., Yagi T., et al. Annonacin, a natural mitochondrial complex I inhibitor, causes tau pathology in cultured neurons. J. Neurosci. 2007;27:7827-7837.
Not in our library10.1523/jneurosci.1644-07.2007
128.
Kandimalla R., Reddy P.H. Multiple faces of dynamin-related protein 1 and its role in Alzheimer’s disease pathogenesis. Biochim. Biophys. Acta. 2016;1862:814-828.
Not in our library10.1016/j.bbadis.2015.12.018
129.
Kandimalla R., Manczak M., Fry D., Suneetha Y., Sesaki H., Reddy P.H. Reduced dynamin-related protein 1 protects against phosphorylated Tau-induced mitochondrial dysfunction and synaptic damage in Alzheimer’s disease. Hum. Mol. Genet. 2016;25:4881-4897.
Not in our library10.1093/hmg/ddw312
130.
Massano J., Bhatia K.P. Clinical approach to Parkinson’s disease: Features, diagnosis, and principles of management. Cold Spring Harb Perspect Med. 2012;2:a008870.
Not in our library10.1101/cshperspect.a008870
131.
Jellinger K.A. Basic mechanisms of neurodegeneration: A critical update. J. Cell Mol. Med. 2010;14:457-487.
Not in our library10.1111/j.1582-4934.2010.01010.x
132.
Luo Y., Hoffer A., Hoffer B., Qi X. Mitochondria: A Therapeutic Target for Parkinson’s Disease? Int. J. Mol. Sci. 2015;16:20704-20730.
Not in our library10.3390/ijms160920704
133.
Mitochondria and Quality Control Defects in a Mouse Model of Gaucher Disease—Links to Parkinson’s Disease · 2013
No notice
134.
Pickrell A.M., Youle R.J. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson’s disease. Neuron. 2015;85:257-273.
Not in our library10.1016/j.neuron.2014.12.007
135.
Aggregated α-synuclein and complex I deficiency: exploration of their relationship in differentiated neurons · 2015
No notice
136.
Luth E.S., Stavrovskaya I.G., Bartels T., Kristal B.S., Selkoe D.J. Soluble, prefibrillar alpha-synuclein oligomers promote complex I-dependent, Ca2+-induced mitochondrial dysfunction. J. Biol. Chem. 2014;289:21490-21507.
Not in our library10.1074/jbc.m113.545749
137.
Chinta S.J., Mallajosyula J.K., Rane A., Andersen J.K. Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo. Neurosci. Lett. 2010;486:235-239.
Not in our library10.1016/j.neulet.2010.09.061
138.
Hsu L.J., Sagara Y., Arroyo A., Rockenstein E., Sisk A., Mallory M., Wong J., Takenouchi T., Hashimoto M., Masliah E. alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am. J. Pathol. 2000;157:401-410.
Not in our library10.1016/s0002-9440(10)64553-1
139.
Martin L.J., Pan Y., Price A.C., Sterling W., Copeland N.G., Jenkins N.A., Price D.L., Lee M.K. Parkinson’s disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J. Neurosci. 2006;26:41-50.
Not in our library10.1523/jneurosci.4308-05.2006
140.
Devi L., Raghavendran V., Prabhu B.M., Avadhani N.G., Anandatheerthavarada H.K. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J. Biol. Chem. 2008;283:9089-9100.
Not in our library10.1074/jbc.m710012200
141.
Guardia-Laguarta C., Area-Gomez E., Rub C., Liu Y., Magrane J., Becker D., Voos W., Schon E.A., Przedborski S. alpha-Synuclein is localized to mitochondria-associated ER membranes. J. Neurosci. 2014;34:249-259.
Not in our library10.1523/jneurosci.2507-13.2014
142.
Nakamura K., Nemani V.M., Azarbal F., Skibinski G., Levy J.M., Egami K., Munishkina L., Zhang J., Gardner B., Wakabayashi J., et al. Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein. J. Biol. Chem. 2011;286:20710-20726.
Not in our library10.1074/jbc.m110.213538
143.
Mitochondrial dynamics in Parkinson's disease: a role for α-synuclein? · 2017
No notice
144.
Di Maio R., Barrett P.J., Hoffman E.K., Barrett C.W., Zharikov A., Borah A., Hu X., McCoy J., Chu C.T., Burton E.A., et al. alpha-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson’s disease. Sci. Transl. Med. 2016;8:342ra378.
Not in our library10.1126/scitranslmed.aaf3634
145.
Martinez J.H., Alaimo A., Gorojod R.M., Porte Alcon S., Fuentes F., Coluccio Leskow F., Kotler M.L. Drp-1 dependent mitochondrial fragmentation and protective autophagy in dopaminergic SH-SY5Y cells overexpressing alpha-synuclein. Mol. Cell Neurosci. 2018;88:107-117.
Not in our library10.1016/j.mcn.2018.01.004
146.
Mitochondrial division inhibitor-1 is neuroprotective in the A53T-α-synuclein rat model of Parkinson’s disease · 2017
No notice
147.
Zigoneanu I.G., Yang Y.J., Krois A.S., Haque E., Pielak G.J. Interaction of alpha-synuclein with vesicles that mimic mitochondrial membranes. Biochim. Biophys. Acta. 2012;1818:512-519.
Not in our library10.1016/j.bbamem.2011.11.024
148.
Cardiolipin exposure on the outer mitochondrial membrane modulates α-synuclein · 2018
No notice
149.
Chen L., Xie Z., Turkson S., Zhuang X. A53T human alpha-synuclein overexpression in transgenic mice induces pervasive mitochondria macroautophagy defects preceding dopamine neuron degeneration. J. Neurosci. 2015;35:890-905.
Not in our library10.1523/jneurosci.0089-14.2015
150.
Chung S.Y., Kishinevsky S., Mazzulli J.R., Graziotto J., Mrejeru A., Mosharov E.V., Puspita L., Valiulahi P., Sulzer D., Milner T.A., et al. Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and alpha-Synuclein Accumulation. Stem Cell Rep. 2016;7:664-677.
Not in our library10.1016/j.stemcr.2016.08.012
151.
Gispert S., Brehm N., Weil J., Seidel K., Rub U., Kern B., Walter M., Roeper J., Auburger G. Potentiation of neurotoxicity in double-mutant mice with Pink1 ablation and A53T-SNCA overexpression. Hum. Mol. Genet. 2015;24:1061-1076.
Not in our library10.1093/hmg/ddu520
152.
Ferrari R., Kapogiannis D., Huey E.D., Momeni P. FTD and ALS: A tale of two diseases. Curr. Alzheimer Res. 2011;8:273-294.
Not in our library10.2174/156720511795563700
153.
Weishaupt J.H., Hyman T., Dikic I. Common Molecular Pathways in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Trends Mol. Med. 2016;22:769-783.
Not in our library10.1016/j.molmed.2016.07.005
154.
Muyderman H., Chen T. Mitochondrial dysfunction in amyotrophic lateral sclerosis—A valid pharmacological target? Br. J. Pharmacol. 2014;171:2191-2205.
Not in our library10.1111/bph.12476
155.
Keep M., Elmer E., Fong K.S., Csiszar K. Intrathecal cyclosporin prolongs survival of late-stage ALS mice. Brain Res. 2001;894:327-331.
Not in our library10.1016/s0006-8993(01)02012-1
156.
Mattiazzi M., D’Aurelio M., Gajewski C.D., Martushova K., Kiaei M., Beal M.F., Manfredi G. Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice. J. Biol. Chem. 2002;277:29626-29633.
Not in our library10.1074/jbc.m203065200
157.
Menzies F.M., Grierson A.J., Cookson M.R., Heath P.R., Tomkins J., Figlewicz D.A., Ince P.G., Shaw P.J. Selective loss of neurofilament expression in Cu/Zn superoxide dismutase (SOD1) linked amyotrophic lateral sclerosis. J. Neurochem. 2002;82:1118-1128.
Not in our library10.1046/j.1471-4159.2002.01045.x
158.
Knott A.B., Perkins G., Schwarzenbacher R., Bossy-Wetzel E. Mitochondrial fragmentation in neurodegeneration. Nat. Rev. Neurosci. 2008;9:505-518.
Not in our library10.1038/nrn2417
159.
Beal M.F., Ferrante R.J., Browne S.E., Matthews R.T., Kowall N.W., Brown R.H. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann. Neurol. 1997;42:644-654.
Not in our library10.1002/ana.410420416
160.
Beal M.F. Coenzyme Q10 as a possible treatment for neurodegenerative diseases. Free Radic. Res. 2002;36:455-460.
Not in our library10.1080/10715760290021315
161.
Carriedo S.G., Sensi S.L., Yin H.Z., Weiss J.H. AMPA exposures induce mitochondrial Ca(2+) overload and ROS generation in spinal motor neurons in vitro. J. Neurosci. 2000;20:240-250.
Not in our library10.1523/jneurosci.20-01-00240.2000
162.
FUS Transgenic Rats Develop the Phenotypes of Amyotrophic Lateral Sclerosis and Frontotemporal Lobar Degeneration · 2011
No notice
163.
Shan X., Chiang P.M., Price D.L., Wong P.C. Altered distributions of Gemini of coiled bodies and mitochondria in motor neurons of TDP-43 transgenic mice. Proc. Natl. Acad. Sci. USA. 2010;107:16325-16330.
Not in our library10.1073/pnas.1003459107
164.
Xu Y.F., Gendron T.F., Zhang Y.J., Lin W.L., D’Alton S., Sheng H., Casey M.C., Tong J., Knight J., Yu X., et al. Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. J. Neurosci. 2010;30:10851-10859.
Not in our library10.1523/jneurosci.1630-10.2010
165.
Davis S.A., Itaman S., Khalid-Janney C.M., Sherard J.A., Dowell J.A., Cairns N.J., Gitcho M.A. TDP-43 interacts with mitochondrial proteins critical for mitophagy and mitochondrial dynamics. Neurosci. Lett. 2018;678:8-15.
Not in our library10.1016/j.neulet.2018.04.053
166.
McColgan P., Tabrizi S.J. Huntington’s disease: A clinical review. Eur. J. Neurol. 2018;25:24-34.
Not in our library10.1111/ene.13413
167.
Feng X., Luo S., Lu B. Conformation Polymorphism of Polyglutamine Proteins. Trends Biochem. Sci. 2018;43:424-435.
Not in our library10.1016/j.tibs.2018.03.002
168.
Lu B., Palacino J. A novel human embryonic stem cell-derived Huntington’s disease neuronal model exhibits mutant huntingtin (mHTT) aggregates and soluble mHTT-dependent neurodegeneration. FASEB J. 2013;27:1820-1829.
Not in our library10.1096/fj.12-219220
169.
Nagai Y., Inui T., Popiel H.A., Fujikake N., Hasegawa K., Urade Y., Goto Y., Naiki H., Toda T. A toxic monomeric conformer of the polyglutamine protein. Nat. Struct. Mol. Biol. 2007;14:332-340.
Not in our library10.1038/nsmb1215
170.
Miller J., Arrasate M., Shaby B.A., Mitra S., Masliah E., Finkbeiner S. Quantitative relationships between huntingtin levels, polyglutamine length, inclusion body formation, and neuronal death provide novel insight into huntington’s disease molecular pathogenesis. J. Neurosci. 2010;30:10541-10550.
Not in our library10.1523/jneurosci.0146-10.2010
171.
Arrasate M., Mitra S., Schweitzer E.S., Segal M.R., Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature. 2004;431:805-810.
Not in our library10.1038/nature02998
172.
Yano H., Baranov S.V., Baranova O.V., Kim J., Pan Y., Yablonska S., Carlisle D.L., Ferrante R.J., Kim A.H., Friedlander R.M. Inhibition of mitochondrial protein import by mutant huntingtin. Nat. Neurosci. 2014;17:822-831.
Not in our library10.1038/nn.3721
173.
Orr A.L., Li S., Wang C.E., Li H., Wang J., Rong J., Xu X., Mastroberardino P.G., Greenamyre J.T., Li X.J. N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J. Neurosci. 2008;28:2783-2792.
Not in our library10.1523/jneurosci.0106-08.2008
174.
Damiano M., Diguet E., Malgorn C., D’Aurelio M., Galvan L., Petit F., Benhaim L., Guillermier M., Houitte D., Dufour N., et al. A role of mitochondrial complex II defects in genetic models of Huntington’s disease expressing N-terminal fragments of mutant huntingtin. Hum. Mol. Genet. 2013;22:3869-3882.
Not in our library10.1093/hmg/ddt242
175.
Mitochondrial Quality Control in Neurodegenerative Diseases: Focus on Parkinson's Disease and Huntington's Disease · 2018
No notice
176.
Shirendeb U., Reddy A.P., Manczak M., Calkins M.J., Mao P., Tagle D.A., Reddy P.H. Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington’s disease: Implications for selective neuronal damage. Hum. Mol. Genet. 2011;20:1438-1455.
Not in our library10.1093/hmg/ddr024
177.
Song W., Chen J., Petrilli A., Liot G., Klinglmayr E., Zhou Y., Poquiz P., Tjong J., Pouladi M.A., Hayden M.R., et al. Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity. Nat. Med. 2011;17:377-382.
Not in our library10.1038/nm.2313
178.
Dynamics of Dynamin-Related Protein 1 in Alzheimer’s Disease and Other Neurodegenerative Diseases · 2019
No notice
179.
Moreira P.I., Siedlak S.L., Wang X., Santos M.S., Oliveira C.R., Tabaton M., Nunomura A., Szweda L.I., Aliev G., Smith M.A., et al. Increased autophagic degradation of mitochondria in Alzheimer disease. Autophagy. 2007;3:614-615.
Not in our library10.4161/auto.4872
180.
Moreira P.I., Siedlak S.L., Wang X., Santos M.S., Oliveira C.R., Tabaton M., Nunomura A., Szweda L.I., Aliev G., Smith M.A., et al. Autophagocytosis of mitochondria is prominent in Alzheimer disease. J. Neuropathol. Exp. Neurol. 2007;66:525-532.
Not in our library10.1097/01.jnen.0000240476.73532.b0
181.
Martin-Maestro P., Gargini R., Perry G., Avila J., Garcia-Escudero V. PARK2 enhancement is able to compensate mitophagy alterations found in sporadic Alzheimer’s disease. Hum. Mol. 2016;25:792-806.
Not in our library10.1093/hmg/ddv616
182.
Monteiro-Cardoso V.F., Oliveira M.M., Melo T., Domingues M.R., Moreira P.I., Ferreiro E., Peixoto F., Videira R.A. Cardiolipin profile changes are associated to the early synaptic mitochondrial dysfunction in Alzheimer’s disease. J. Alzheimers Dis. 2015;43:1375-1392.
Not in our library10.3233/jad-141002
183.
Lee S., Sato Y., Nixon R.A. Lysosomal proteolysis inhibition selectively disrupts axonal transport of degradative organelles and causes an Alzheimer’s-like axonal dystrophy. J. Neurosci. 2011;31:7817-7830.
Not in our library10.1523/jneurosci.6412-10.2011
184.
Nixon R.A., Yang D.S. Autophagy failure in Alzheimer’s disease—Locating the primary defect. Neurobiol. Dis. 2011;43:38-45.
Not in our library10.1016/j.nbd.2011.01.021
185.
Nixon R.A. The role of autophagy in neurodegenerative disease. Nat. Med. 2013;19:983-997.
Not in our library10.1038/nm.3232
186.
Tammineni P., Jeong Y.Y., Feng T., Aikal D., Cai Q. Impaired axonal retrograde trafficking of the retromer complex augments lysosomal deficits in Alzheimer’s disease neurons. Hum. Mol. Genet. 2017;26:4352-4366.
Not in our library10.1093/hmg/ddx321
187.
Small S.A., Petsko G.A. Retromer in Alzheimer disease, Parkinson disease and other neurological disorders. Nat. Rev. Neurosci. 2015;16:126-132.
Not in our library10.1038/nrn3896
188.
Corsetti V., Florenzano F., Atlante A., Bobba A., Ciotti M.T., Natale F., Della Valle F., Borreca A., Manca A., Meli G., et al. NH2-truncated human tau induces deregulated mitophagy in neurons by aberrant recruitment of Parkin and UCHL-1: Implications in Alzheimer’s disease. Hum. Mol. Genet. 2015;24:3058-3081.
Not in our library10.1093/hmg/ddv059
189.
Tau accumulation impairs mitophagy via increasing mitochondrial membrane potential and reducing mitochondrial Parkin · 2016
No notice
190.
Cummins N., Tweedie A., Zuryn S., Bertran-Gonzalez J., Gotz J. Disease-associated tau impairs mitophagy by inhibiting Parkin translocation to mitochondria. EMBO J. 2019;38.
Not in our library10.15252/embj.201899360
191.
Fang E.F., Hou Y., Palikaras K., Adriaanse B.A., Kerr J.S., Yang B., Lautrup S., Hasan-Olive M.M., Caponio D., Dan X., et al. Mitophagy inhibits amyloid-beta and tau pathology and reverses cognitive deficits in models of Alzheimer’s disease. Nat. Neurosci. 2019;22:401-412.
Not in our library10.1038/s41593-018-0332-9
192.
Lindstrom V., Gustafsson G., Sanders L.H., Howlett E.H., Sigvardson J., Kasrayan A., Ingelsson M., Bergstrom J., Erlandsson A. Extensive uptake of alpha-synuclein oligomers in astrocytes results in sustained intracellular deposits and mitochondrial damage. Mol. Cell Neurosci. 2017;82:143-156.
Not in our library10.1016/j.mcn.2017.04.009
193.
Pukass K., Goldbaum O., Richter-Landsberg C. Mitochondrial impairment and oxidative stress compromise autophagosomal degradation of alpha-synuclein in oligodendroglial cells. J. Neurochem. 2015;135:194-205.
Not in our library10.1111/jnc.13256
194.
Sherer T.B., Betarbet R., Stout A.K., Lund S., Baptista M., Panov A.V., Cookson M.R., Greenamyre J.T. An in vitro model of Parkinson’s disease: Linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J. Neurosci. 2002;22:7006-7015.
Not in our library10.1523/jneurosci.22-16-07006.2002
195.
Hsieh C.H., Shaltouki A., Gonzalez A.E., Bettencourt da Cruz A., Burbulla L.F., St Lawrence E., Schule B., Krainc D., Palmer T.D., Wang X. Functional Impairment in Miro Degradation and Mitophagy Is a Shared Feature in Familial and Sporadic Parkinson’s Disease. Cell Stem Cell. 2016;19:709-724.
Not in our library10.1016/j.stem.2016.08.002
196.
Burchell V.S., Nelson D.E., Sanchez-Martinez A., Delgado-Camprubi M., Ivatt R.M., Pogson J.H., Randle S.J., Wray S., Lewis P.A., Houlden H., et al. The Parkinson’s disease-linked proteins Fbxo7 and Parkin interact to mediate mitophagy. Nat. Neurosci. 2013;16:1257-1265.
Not in our library10.1038/nn.3489
197.
Zhou Z.D., Xie S.P., Sathiyamoorthy S., Saw W.T., Sing T.Y., Ng S.H., Chua H.P., Tang A.M., Shaffra F., Li Z., et al. F-box protein 7 mutations promote protein aggregation in mitochondria and inhibit mitophagy. Hum. Mol. Genet. 2015;24:6314-6330.
Not in our library10.1093/hmg/ddv340
198.
Bender A., Krishnan K.J., Morris C.M., Taylor G.A., Reeve A.K., Perry R.H., Jaros E., Hersheson J.S., Betts J., Klopstock T., et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat. Genet. 2006;38:515-517.
Not in our library10.1038/ng1769
199.
Dagda R.K., Cherra S.J., Kulich S.M., Tandon A., Park D., Chu C.T. Loss of PINK1 function promotes mitophagy through effects on oxidative stress and mitochondrial fission. J. Biol. Chem. 2009;284:13843-13855.
Not in our library10.1074/jbc.m808515200
200.
Dagda R.K., Zhu J., Kulich S.M., Chu C.T. Mitochondrially localized ERK2 regulates mitophagy and autophagic cell stress: Implications for Parkinson’s disease. Autophagy. 2008;4:770-782.
Not in our library10.4161/auto.6458
201.
Osellame L.D., Duchen M.R. Defective quality control mechanisms and accumulation of damaged mitochondria link Gaucher and Parkinson diseases. Autophagy. 2013;9:1633-1635.
Not in our library10.4161/auto.25878
202.
Zhu J.H., Horbinski C., Guo F., Watkins S., Uchiyama Y., Chu C.T. Regulation of autophagy by extracellular signal-regulated protein kinases during 1-methyl-4-phenylpyridinium-induced cell death. Am. J. Pathol. 2007;170:75-86.
Not in our library10.2353/ajpath.2007.060524
203.
Chu C.T. Multiple pathways for mitophagy: A neurodegenerative conundrum for Parkinson’s disease. Neurosci. Lett. 2019;697:66-71.
Not in our library10.1016/j.neulet.2018.04.004
204.
Whitworth A.J., Theodore D.A., Greene J.C., Benes H., Wes P.D., Pallanck L.J. Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a Drosophila model of Parkinson’s disease. Proc. Natl. Acad. Sci. USA. 2005;102:8024-8029.
Not in our library10.1073/pnas.0501078102
205.
Cha G.H., Kim S., Park J., Lee E., Kim M., Lee S.B., Kim J.M., Chung J., Cho K.S. Parkin negatively regulates JNK pathway in the dopaminergic neurons of Drosophila. Proc. Natl. Acad. Sci. USA. 2005;102:10345-10350.
Not in our library10.1073/pnas.0500346102
206.
Greene J.C., Whitworth A.J., Kuo I., Andrews L.A., Feany M.B., Pallanck L.J. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc. Natl. Acad. Sci. USA. 2003;100:4078-4083.
Not in our library10.1073/pnas.0737556100
207.
Pesah Y., Pham T., Burgess H., Middlebrooks B., Verstreken P., Zhou Y., Harding M., Bellen H., Mardon G. Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress. Development. 2004;131:2183-2194.
Not in our library10.1242/dev.01095
208.
Yang Y., Gehrke S., Imai Y., Huang Z., Ouyang Y., Wang J.W., Yang L., Beal M.F., Vogel H., Lu B. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc. Natl. Acad. Sci. USA. 2006;103:10793-10798.
Not in our library10.1073/pnas.0602493103
209.
Deficiency of parkin and PINK1 impairs age-dependent mitophagy in Drosophila · 2018
No notice
210.
Phenotypic characterization of recessive gene knockout rat models of Parkinson's disease · 2014
Not checked
211.
Pickrell A.M., Huang C.H., Kennedy S.R., Ordureau A., Sideris D.P., Hoekstra J.G., Harper J.W., Youle R.J. Endogenous Parkin Preserves Dopaminergic Substantia Nigral Neurons following Mitochondrial DNA Mutagenic Stress. Neuron. 2015;87:371-381.
Not in our library10.1016/j.neuron.2015.06.034
212.
Rogers R.S., Tungtur S., Tanaka T., Nadeau L.L., Badawi Y., Wang H., Ni H.M., Ding W.X., Nishimune H. Impaired Mitophagy Plays a Role in Denervation of Neuromuscular Junctions in ALS Mice. Front. Neurosci. 2017;11:473.
Not in our library10.3389/fnins.2017.00473
213.
Xie Y., Zhou B., Lin M.Y., Wang S., Foust K.D., Sheng Z.H. Endolysosomal Deficits Augment Mitochondria Pathology in Spinal Motor Neurons of Asymptomatic fALS Mice. Neuron. 2015;87:355-370.
Not in our library10.1016/j.neuron.2015.06.026
214.
Palomo G.M., Granatiero V., Kawamata H., Konrad C., Kim M., Arreguin A.J., Zhao D., Milner T.A., Manfredi G. Parkin is a disease modifier in the mutant SOD1 mouse model of ALS. EMBO Mol. Med. 2018;10.
Not in our library10.15252/emmm.201808888
215.
Lysine 27 Ubiquitination of the Mitochondrial Transport Protein Miro Is Dependent on Serine 65 of the Parkin Ubiquitin Ligase · 2014
No notice
216.
Bingol B., Tea J.S., Phu L., Reichelt M., Bakalarski C.E., Song Q.H., Foreman O., Kirkpatrick D.S., Sheng M.G. The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy. Nature. 2014;510:370.
Not in our library10.1038/nature13418
217.
Parkinson's Disease–Associated Kinase PINK1 Regulates Miro Protein Level and Axonal Transport of Mitochondria · 2012
No notice
218.
Wang X., Winter D., Ashrafi G., Schlehe J., Wong Y.L., Selkoe D., Rice S., Steen J., LaVoie M.J., Schwarz T.L. PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility. Cell. 2011;147:893-906.
Not in our library10.1016/j.cell.2011.10.018
219.
Miro1 Deficiency in Amyotrophic Lateral Sclerosis · 2015
Not checked
220.
Moller A., Bauer C.S., Cohen R.N., Webster C.P., De Vos K.J. Amyotrophic lateral sclerosis-associated mutant SOD1 inhibits anterograde axonal transport of mitochondria by reducing Miro1 levels. Hum. Mol. Genet. 2017;26:4668-4679.
Not in our library10.1093/hmg/ddx348
221.
Nguyen T.T., Oh S.S., Weaver D., Lewandowska A., Maxfield D., Schuler M.H., Smith N.K., Macfarlane J., Saunders G., Palmer C.A., et al. Loss of Miro1-directed mitochondrial movement results in a novel murine model for neuron disease. Proc. Natl. Acad. Sci. USA. 2014;111:E3631-E3640.
Not in our library10.1073/pnas.1402449111
222.
Maruyama H., Morino H., Ito H., Izumi Y., Kato H., Watanabe Y., Kinoshita Y., Kamada M., Nodera H., Suzuki H., et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature. 2010;465:223-226.
Not in our library10.1038/nature08971
223.
Freischmidt A., Wieland T., Richter B., Ruf W., Schaeffer V., Muller K., Marroquin N., Nordin F., Hubers A., Weydt P., et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat. Neurosci. 2015;18:631-636.
Not in our library10.1038/nn.4000
224.
Fecto F., Yan J., Vemula S.P., Liu E., Yang Y., Chen W., Zheng J.G., Shi Y., Siddique N., Arrat H., et al. SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch. Neurol. 2011;68:1440-1446.
Not in our library10.1001/archneurol.2011.250
225.
Impaired GAPDH‐induced mitophagy contributes to the pathology of Huntington's disease · 2015
No notice
226.
Ross C.A., Tabrizi S.J. Huntington’s disease: From molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10:83-98.
Not in our library10.1016/s1474-4422(10)70245-3
227.
Martinez-Vicente M., Talloczy Z., Wong E., Tang G., Koga H., Kaushik S., de Vries R., Arias E., Harris S., Sulzer D., et al. Cargo recognition failure is responsible for inefficient autophagy in Huntington’s disease. Nat. Neurosci. 2010;13:567-576.
Not in our library10.1038/nn.2528
228.
Rui Y.N., Xu Z., Patel B., Chen Z., Chen D., Tito A., David G., Sun Y., Stimming E.F., Bellen H.J., et al. Huntingtin functions as a scaffold for selective macroautophagy. Nat. Cell Biol. 2015;17:262-275.
Not in our library10.1038/ncb3101
229.
Mattson M.P., Gleichmann M., Cheng A. Mitochondria in neuroplasticity and neurological disorders. Neuron. 2008;60:748-766.
Not in our library10.1016/j.neuron.2008.10.010
230.
Fang E.F., Lautrup S., Hou Y., Demarest T.G., Croteau D.L., Mattson M.P., Bohr V.A. NAD(+) in Aging: Molecular Mechanisms and Translational Implications. Trends Mol. Med. 2017;23:899-916.
Not in our library10.1016/j.molmed.2017.08.001
231.
Gupta V.K., Scheunemann L., Eisenberg T., Mertel S., Bhukel A., Koemans T.S., Kramer J.M., Liu K.S., Schroeder S., Stunnenberg H.G., et al. Restoring polyamines protects from age-induced memory impairment in an autophagy-dependent manner. Nat. Neurosci. 2013;16:1453-1460.
Not in our library10.1038/nn.3512
232.
Madeo F., Eisenberg T., Pietrocola F., Kroemer G. Spermidine in health and disease. Science. 2018;359.
Not in our library10.1126/science.aan2788
233.
Gong B., Pan Y., Vempati P., Zhao W., Knable L., Ho L., Wang J., Sastre M., Ono K., Sauve A.A., et al. Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-gamma coactivator 1alpha regulated beta-secretase 1 degradation and mitochondrial gene expression in Alzheimer’s mouse models. Neurobiol. Aging. 2013;34:1581-1588.
Not in our library10.1016/j.neurobiolaging.2012.12.005
234.
Hou Y., Lautrup S., Cordonnier S., Wang Y., Croteau D.L., Zavala E., Zhang Y., Moritoh K., O’Connell J.F., Baptiste B.A., et al. NAD(+) supplementation normalizes key Alzheimer’s features and DNA damage responses in a new AD mouse model with introduced DNA repair deficiency. Proc. Natl. Acad. Sci. USA. 2018;115:E1876-E1885.
Not in our library10.1073/pnas.1718819115
235.
Liu D., Pitta M., Jiang H., Lee J.H., Zhang G., Chen X., Kawamoto E.M., Mattson M.P. Nicotinamide forestalls pathology and cognitive decline in Alzheimer mice: Evidence for improved neuronal bioenergetics and autophagy procession. Neurobiol. Aging. 2013;34:1564-1580.
Not in our library10.1016/j.neurobiolaging.2012.11.020
236.
Turunc Bayrakdar E., Uyanikgil Y., Kanit L., Koylu E., Yalcin A. Nicotinamide treatment reduces the levels of oxidative stress, apoptosis, and PARP-1 activity in Abeta(1-42)-induced rat model of Alzheimer’s disease. Free Radic. Res. 2014;48:146-158.
Not in our library10.3109/10715762.2013.857018
237.
Schondorf D.C., Ivanyuk D., Baden P., Sanchez-Martinez A., De Cicco S., Yu C., Giunta I., Schwarz L.K., Di Napoli G., Panagiotakopoulou V., et al. The NAD+ Precursor Nicotinamide Riboside Rescues Mitochondrial Defects and Neuronal Loss in iPSC and Fly Models of Parkinson’s Disease. Cell Rep. 2018;23:2976-2988.
Not in our library10.1016/j.celrep.2018.05.009
238.
Spermidine coupled with exercise rescues skeletal muscle atrophy from D-gal-induced aging rats through enhanced autophagy and reduced apoptosis via AMPK-FOXO3a signal pathway · 2017
No notice
239.
Eisenberg T., Knauer H., Schauer A., Buttner S., Ruckenstuhl C., Carmona-Gutierrez D., Ring J., Schroeder S., Magnes C., Antonacci L., et al. Induction of autophagy by spermidine promotes longevity. Nat. Cell Biol. 2009;11:1305-1314.
Not in our library10.1038/ncb1975
240.
Geisler J.G., Marosi K., Halpern J., Mattson M.P. DNP, mitochondrial uncoupling, and neuroprotection: A little dab’ll do ya. Alzheimers Dement. 2017;13:582-591.
Not in our library10.1016/j.jalz.2016.08.001
241.
Duan W., Mattson M.P. Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson’s disease. J. Neurosci. Res. 1999;57:195-206.
Not in our library10.1002/(sici)1097-4547(19990715)57:2<195::aid-jnr5>3.0.co;2-p
242.
2-Deoxy-D-Glucose Treatment Induces Ketogenesis, Sustains Mitochondrial Function, and Reduces Pathology in Female Mouse Model of Alzheimer's Disease · 2011
No notice
243.
Roth G.S., Ingram D.K. Manipulation of health span and function by dietary caloric restriction mimetics. Ann. N. Y. Acad. Sci. 2016;1363:5-10.
Not in our library10.1111/nyas.12834
244.
Ravikumar B., Vacher C., Berger Z., Davies J.E., Luo S., Oroz L.G., Scaravilli F., Easton D.F., Duden R., O’Kane C.J., et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet. 2004;36:585-595.
Not in our library10.1038/ng1362
245.
Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease · 2010
Corrected
246.
Howell J.J., Hellberg K., Turner M., Talbott G., Kolar M.J., Ross D.S., Hoxhaj G., Saghatelian A., Shaw R.J., Manning B.D. Metformin Inhibits Hepatic mTORC1 Signaling via Dose-Dependent Mechanisms Involving AMPK and the TSC Complex. Cell Metab. 2017;25:463-471.
Not in our library10.1016/j.cmet.2016.12.009
247.
Zheng Z., Chen H., Li J., Li T., Zheng B., Zheng Y., Jin H., He Y., Gu Q., Xu X. Sirtuin 1-mediated cellular metabolic memory of high glucose via the LKB1/AMPK/ROS pathway and therapeutic effects of metformin. Diabetes. 2012;61:217-228.
Not in our library10.2337/db11-0416
248.
Song Y.M., Lee W.K., Lee Y.H., Kang E.S., Cha B.S., Lee B.W. Metformin Restores Parkin-Mediated Mitophagy, Suppressed by Cytosolic p53. Int. J. Mol. Sci. 2016;17:122.
Not in our library10.3390/ijms17010122
249.
Ryu D., Mouchiroud L., Andreux P.A., Katsyuba E., Moullan N., Nicolet-Dit-Felix A.A., Williams E.G., Jha P., Lo Sasso G., Huzard D., et al. Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Nat. Med. 2016;22:879-888.
Not in our library10.1038/nm.4132
250.
Morselli E., Marino G., Bennetzen M.V., Eisenberg T., Megalou E., Schroeder S., Cabrera S., Benit P., Rustin P., Criollo A., et al. Spermidine and resveratrol induce autophagy by distinct pathways converging on the acetylproteome. J. Cell Biol. 2011;192:615-629.
Not in our library10.1083/jcb.201008167
251.
Lonskaya I., Hebron M.L., Desforges N.M., Schachter J.B., Moussa C.E. Nilotinib-induced autophagic changes increase endogenous parkin level and ubiquitination, leading to amyloid clearance. J. Mol. Med. (Berl.). 2014;92:373-386.
Not in our library10.1007/s00109-013-1112-3
252.
Ko H.S., Lee Y., Shin J.H., Karuppagounder S.S., Gadad B.S., Koleske A.J., Pletnikova O., Troncoso J.C., Dawson V.L., Dawson T.M. Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin’s ubiquitination and protective function. Proc. Natl. Acad. Sci. USA. 2010;107:16691-16696.
Not in our library10.1073/pnas.1006083107
253.
Tyrosine kinase inhibition increases functional parkin‐Beclin‐1 interaction and enhances amyloid clearance and cognitive performance · 2013
No notice
254.
Wenqiang C., Lonskaya I., Hebron M.L., Ibrahim Z., Olszewski R.T., Neale J.H., Moussa C.E. Parkin-mediated reduction of nuclear and soluble TDP-43 reverses behavioral decline in symptomatic mice. Hum. Mol. Genet. 2014;23:4960-4969.
Not in our library10.1093/hmg/ddu211
255.
Kelso G.F., Porteous C.M., Coulter C.V., Hughes G., Porteous W.K., Ledgerwood E.C., Smith R.A., Murphy M.P. Selective targeting of a redox-active ubiquinone to mitochondria within cells: Antioxidant and antiapoptotic properties. J. Biol. Chem. 2001;276:4588-4596.
Not in our library10.1074/jbc.m009093200
256.
Miquel E., Cassina A., Martinez-Palma L., Souza J.M., Bolatto C., Rodriguez-Bottero S., Logan A., Smith R.A., Murphy M.P., Barbeito L., et al. Neuroprotective effects of the mitochondria-targeted antioxidant MitoQ in a model of inherited amyotrophic lateral sclerosis. Free Radic. Biol. Med. 2014;70:204-213.
Not in our library10.1016/j.freeradbiomed.2014.02.019
257.
McManus M.J., Murphy M.P., Franklin J.L. The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer’s disease. J. Neurosci. 2011;31:15703-15715.
Not in our library10.1523/jneurosci.0552-11.2011
258.
Ng L.F., Gruber J., Cheah I.K., Goo C.K., Cheong W.F., Shui G., Sit K.P., Wenk M.R., Halliwell B. The mitochondria-targeted antioxidant MitoQ extends lifespan and improves healthspan of a transgenic Caenorhabditis elegans model of Alzheimer disease. Free Radic. Biol. Med. 2014;71:390-401.
Not in our library10.1016/j.freeradbiomed.2014.03.003

Cited by papers we hold 11

Mitochondrial Dynamics in Neurodegenerative Diseases: Unraveling the Role of Fusion and Fission Processes · 2023
No notice
Regulation of neuronal autophagy and the implications in neurodegenerative diseases · 2022
Not checked
Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response · 2022
No notice
Epigallocatechin-3-Gallate (EGCG): New Therapeutic Perspectives for Neuroprotection, Aging, and Neuroinflammation for the Modern Age · 2022
No notice
Mitophagy and Oxidative Stress: The Role of Aging · 2021
No notice
Defective Autophagy and Mitophagy in Aging and Alzheimer’s Disease · 2021
No notice
Role of lysosomes in physiological activities, diseases, and therapy · 2021
No notice
Mitochondrial Dysfunction and Oxidative Stress in Alzheimer’s Disease · 2021
No notice
Alzheimer’s Disease Pathogenesis: Role of Autophagy and Mitophagy Focusing in Microglia · 2021
No notice
Mitochondrial Dysfunction as a Driver of Cognitive Impairment in Alzheimer’s Disease · 2021
No notice
Regulation of Mammalian Mitochondrial Dynamics: Opportunities and Challenges · 2020
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.